https://www.stadtwiki-strausberg.de/index.php?action=history&feed=atom&title=Understanding_5CLADBA%3A_An_Overview_For_Responsible_Research 2026-06-17T03:08:35Z Versionsgeschichte dieser Seite in Stadtwiki Strausberg MediaWiki 1.33.1 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28648&oldid=prev 2026-06-04T09:01:34Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 4. Juni 2026, 09:01 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Thirty minutes prior to the training sessions</del>, <del class="diffchange diffchange-inline">rats received an injection of either vehicle or Δ9</del>-<del class="diffchange diffchange-inline">THC and were subsequently placed in the behavior</del>-<del class="diffchange diffchange-inline">testing chambers</del>, <del class="diffchange diffchange-inline">where food (45</del>-<del class="diffchange diffchange-inline">mg food pellets; Bio-Serve, Frenchtown, NJ) was available as </del>a <del class="diffchange diffchange-inline">reinforcer </del>for <del class="diffchange diffchange-inline">every ten responses (FR10) on a designated injection appropriate lever</del>. <del class="diffchange diffchange-inline">A houselight was centered over the hopper close </del>to the <del class="diffchange diffchange-inline">ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect </del>to <del class="diffchange diffchange-inline">those producing at least 50% depression compared to vehicle control. Twenty</del>-<del class="diffchange diffchange-inline">four male Sprague-Dawley rats were obtained from Envigo (Houston, TX)</del>. <del class="diffchange diffchange-inline">4F ADB Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age </del>and <del class="diffchange diffchange-inline">maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Our findings revealed that both victims consumed large amounts </del>of <del class="diffchange diffchange-inline">alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2</del>.<del class="diffchange diffchange-inline">11 and 2</del>.<del class="diffchange diffchange-inline">49 g</del>/<del class="diffchange diffchange-inline">L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico</del>-<del class="diffchange diffchange-inline">legal autopsies</del>. <del class="diffchange diffchange-inline">Elegans demonstrated the ability to form all of the in-vivo metabolites and has the </del>potential <del class="diffchange diffchange-inline">to be used as a complementary model to predict </del>and <del class="diffchange diffchange-inline">characterize human metabolites</del>, <del class="diffchange diffchange-inline">as well as identifying possible drug toxicities for emerging SCBs</del>. <del class="diffchange diffchange-inline">Thus</del>, <del class="diffchange diffchange-inline">identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio</del>. <del class="diffchange diffchange-inline">Moreover</del>, <del class="diffchange diffchange-inline">genetic makeup, physiological conditions (age, gender 4F ADB </del>and <del class="diffchange diffchange-inline">ethnicity)</del>, <del class="diffchange diffchange-inline">environmental influences (diet) and pathological factors (liver diseases</del>, <del class="diffchange diffchange-inline">diabetes</del>, <del class="diffchange diffchange-inline">and obesity</del>) <del class="diffchange diffchange-inline">would further complicate the metabolism of drugs</del>. <del class="diffchange diffchange-inline">It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias </del>for <del class="diffchange diffchange-inline">each metabolite.&lt;br&gt;Data concerning the combined effects of SCRAs and other substances are highly limited</del>, <del class="diffchange diffchange-inline">which renders forensic evaluation </del>of <del class="diffchange diffchange-inline">possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims </del>were <del class="diffchange diffchange-inline">brothers who were both found deceased after consuming 4F-MDMB-BINACA </del>and <del class="diffchange diffchange-inline">ethanol</del>. <del class="diffchange diffchange-inline">These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus</del>, <del class="diffchange diffchange-inline">liver microsomes </del>and <del class="diffchange diffchange-inline">confirmed using urine samples. This article does not contain any studies with human participants or animals </del>performed <del class="diffchange diffchange-inline">by any of </del>the <del class="diffchange diffchange-inline">author</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;All of the compounds tested in </del>the <del class="diffchange diffchange-inline">present study depressed locomotor activity as </del>is <del class="diffchange diffchange-inline">typical for other synthetic cannabinoids </del>(<del class="diffchange diffchange-inline">see review by Wiley et al</del>., <del class="diffchange diffchange-inline">2017)</del>. <del class="diffchange diffchange-inline">Average horizontal activity counts/10 min as a function of time </del>(10 <del class="diffchange diffchange-inline">min bins) and dose. Depressant effects of 1.33 </del>mg/kg <del class="diffchange diffchange-inline">were observed within 10 min following administration </del>and <del class="diffchange diffchange-inline">peak depressant effects were [https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/ 4F ADB] observed between 0–30 min. Duration of </del>the <del class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0</del>.<del class="diffchange diffchange-inline">1 mg/kg </del>to <del class="diffchange diffchange-inline">2</del>.<del class="diffchange diffchange-inline">5 h following 1 mg/k</del>&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">In the present study</del>, <del class="diffchange diffchange-inline">we performed various methods based on animal behavioral testing including FOB test for general behavioral observation</del>, <del class="diffchange diffchange-inline">rotarod test</del>, <del class="diffchange diffchange-inline">locomotor activity test for motor function evaluation</del>, <del class="diffchange diffchange-inline">and water</del>-<del class="diffchange diffchange-inline">maze test for learning</del>/<del class="diffchange diffchange-inline">memory evaluation</del>. <del class="diffchange diffchange-inline">Known for its stability </del>and <del class="diffchange diffchange-inline">consistent composition</del>, <del class="diffchange diffchange-inline">this compound is frequently utilized by professionals seeking reliable materials </del>for <del class="diffchange diffchange-inline">laboratory</del>-<del class="diffchange diffchange-inline">based analytical studies</del>. <del class="diffchange diffchange-inline">In this study</del>, <del class="diffchange diffchange-inline">histopathological evaluation was performed to confirm </del>the <del class="diffchange diffchange-inline">possibility of neurotoxicity </del>of the <del class="diffchange diffchange-inline">tested substances by hematoxylin </del>and <del class="diffchange diffchange-inline">eosin staining method from collected brain samples</del>. <del class="diffchange diffchange-inline">In </del>the <del class="diffchange diffchange-inline">present study, we evaluated </del>the <del class="diffchange diffchange-inline">neurotoxicity </del>of two <del class="diffchange diffchange-inline">synthetic cannabinoids (JWH-081 and JWH-210) through observation </del>of <del class="diffchange diffchange-inline">various behavioral changes </del>and <del class="diffchange diffchange-inline">analysis </del>of <del class="diffchange diffchange-inline">histopathological changes using experimental mice with various doses </del>(0.1<del class="diffchange diffchange-inline">, </del>1<del class="diffchange diffchange-inline">, 5 mg</del>/<del class="diffchange diffchange-inline">kg</del>). <del class="diffchange diffchange-inline">Selecting powder JWH</del>-<del class="diffchange diffchange-inline">210 demands careful evaluation </del>of <del class="diffchange diffchange-inline">purity</del>, <del class="diffchange diffchange-inline">legality</del>, <del class="diffchange diffchange-inline">and supplier credibility</del>. <del class="diffchange diffchange-inline">Prices for research</del>-<del class="diffchange diffchange-inline">grade JWH</del>-<del class="diffchange diffchange-inline">210 vary significantly based </del>on <del class="diffchange diffchange-inline">quantity, purity</del>, and <del class="diffchange diffchange-inline">vendor complianc</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">In summary</ins>, <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder stands out as a high</ins>-<ins class="diffchange diffchange-inline">quality research compound designed for professionals who demand accuracy, consistency</ins>, <ins class="diffchange diffchange-inline">and reliability. This commitment to cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com blog post quality makes it </ins>a <ins class="diffchange diffchange-inline">trusted option </ins>for <ins class="diffchange diffchange-inline">professionals who require dependable compounds for their work</ins>. <ins class="diffchange diffchange-inline">From sourcing raw materials </ins>to <ins class="diffchange diffchange-inline">final packaging, every stage of </ins>the <ins class="diffchange diffchange-inline">process is monitored </ins>to <ins class="diffchange diffchange-inline">ensure compliance with laboratory</ins>-<ins class="diffchange diffchange-inline">grade expectations</ins>. <ins class="diffchange diffchange-inline">This makes it an ideal choice for laboratories that prioritize both efficiency </ins>and <ins class="diffchange diffchange-inline">compliance with research standards.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Key Features and Specifications to Evaluate </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">In case </ins>of <ins class="diffchange diffchange-inline">cannabis or Δ9-tetrahydrocannabinol, there are many cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com [https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com</ins>/ <ins class="diffchange diffchange-inline">cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb</ins>.<ins class="diffchange diffchange-inline">com blog post] post previous studies regarding with their dependence </ins>potential and <ins class="diffchange diffchange-inline">neurotoxicity (Cororan</ins>, <ins class="diffchange diffchange-inline">et al</ins>., <ins class="diffchange diffchange-inline">1974; Harris, et al</ins>., <ins class="diffchange diffchange-inline">1974; Leite </ins>and <ins class="diffchange diffchange-inline">Culini</ins>, <ins class="diffchange diffchange-inline">1974; Hutcheson</ins>, <ins class="diffchange diffchange-inline">et al.</ins>, <ins class="diffchange diffchange-inline">1998</ins>). <ins class="diffchange diffchange-inline">After administering test substances once every other day </ins>for <ins class="diffchange diffchange-inline">10 days</ins>, <ins class="diffchange diffchange-inline">brain samples </ins>of <ins class="diffchange diffchange-inline">mice </ins>were <ins class="diffchange diffchange-inline">collected, especially at nucleus accumbens </ins>and <ins class="diffchange diffchange-inline">hippocampus regions</ins>. <ins class="diffchange diffchange-inline">Drug was administered 5 times every other day</ins>, and <ins class="diffchange diffchange-inline">the first trial was </ins>performed <ins class="diffchange diffchange-inline">2 h after </ins>the <ins class="diffchange diffchange-inline">last administration.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">How to Choose Powder JWH-210 </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">When learning how to choose powder JWH-210, </ins>the <ins class="diffchange diffchange-inline">most critical factor </ins>is <ins class="diffchange diffchange-inline">verifying high chemical purity </ins>(<ins class="diffchange diffchange-inline">≥98%) from a reputable supplier with independent lab testing</ins>. <ins class="diffchange diffchange-inline">We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31</ins>, <ins class="diffchange diffchange-inline">and Cd74p41, while JWH-030 increased Cd3g levels</ins>. <ins class="diffchange diffchange-inline">JWH-210 </ins>(10 mg/kg<ins class="diffchange diffchange-inline">, 3 days, i.p.) is more likely to have cytotoxicity </ins>and <ins class="diffchange diffchange-inline">reduce lymphoid organ weight than JWH</ins>-<ins class="diffchange diffchange-inline">030 of ICR mice in vivo</ins>. <ins class="diffchange diffchange-inline">Users are expected to handle </ins>the <ins class="diffchange diffchange-inline">compound in accordance with all applicable regulations and safety guidelines within their jurisdiction</ins>. <ins class="diffchange diffchange-inline">It is important </ins>to <ins class="diffchange diffchange-inline">note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only</ins>. <ins class="diffchange diffchange-inline">Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramoun</ins>&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Figure 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana</ins>, <ins class="diffchange diffchange-inline">but have different chemical structures unrelated to Δ9-THC</ins>, <ins class="diffchange diffchange-inline">different metabolism</ins>, <ins class="diffchange diffchange-inline">and often greater toxicity (Fantegrossi et al.</ins>, <ins class="diffchange diffchange-inline">2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9</ins>-<ins class="diffchange diffchange-inline">tetrahydrocannabinol (3 mg</ins>/<ins class="diffchange diffchange-inline">kg, 30-min pretreatment)</ins>. <ins class="diffchange diffchange-inline">5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, </ins>and <ins class="diffchange diffchange-inline">AMB-FUBINACA (also known as FUB-AMB</ins>, <ins class="diffchange diffchange-inline">MMB-FUBINACA) were tested </ins>for <ins class="diffchange diffchange-inline">in vivo cannabinoid</ins>-<ins class="diffchange diffchange-inline">like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;§ (3) of the Hungarian act of Forensic Experts (2016</ins>.<ins class="diffchange diffchange-inline">XXIX)</ins>, the <ins class="diffchange diffchange-inline">data </ins>of the <ins class="diffchange diffchange-inline">reported case can be utilized freely for scientific </ins>and <ins class="diffchange diffchange-inline">educational purposes without special ethical permission</ins>. <ins class="diffchange diffchange-inline">These results indicate that </ins>the <ins class="diffchange diffchange-inline">simultaneous intoxication of SCRA and ethanol directly and exclusively caused </ins>the <ins class="diffchange diffchange-inline">death </ins>of <ins class="diffchange diffchange-inline">the </ins>two <ins class="diffchange diffchange-inline">victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption </ins>of <ins class="diffchange diffchange-inline">SCRAs </ins>and <ins class="diffchange diffchange-inline">ethanol. Several case reports describe that the presence </ins>of <ins class="diffchange diffchange-inline">a little ng/mL </ins>(0<ins class="diffchange diffchange-inline">.37–4</ins>.1<ins class="diffchange diffchange-inline">) of SCRAs and a high—but not lethal—concentration of ethanol (</ins>1<ins class="diffchange diffchange-inline">.45–2.7 g</ins>/<ins class="diffchange diffchange-inline">L) directly and exclusively contributed to the death of the victim [24–27] (Table 2</ins>). <ins class="diffchange diffchange-inline">The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA shortly before their death&lt;br&gt;&lt;br&gt;&lt;br&gt;Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes </ins>of <ins class="diffchange diffchange-inline">Health. It is illegal to sell, distribute</ins>, <ins class="diffchange diffchange-inline">supply</ins>, <ins class="diffchange diffchange-inline">transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016</ins>. <ins class="diffchange diffchange-inline">The corresponding indole core analogue, 4F-MDMB-BICA (4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BUTICA), has also been widely sold as a designer drug by chemical providers </ins>on <ins class="diffchange diffchange-inline">the internet</ins>, <ins class="diffchange diffchange-inline">first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products </ins>and <ins class="diffchange diffchange-inline">sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.&lt;br&gt;Fig.</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28644:rev-28648 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28644&oldid=prev 2026-06-04T09:00:12Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 4. Juni 2026, 09:00 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than the 4F-MDMB-BINACA, indicating monohydroxylation at the butyl side chain (B19/B21) and indazole (B23/B25) moieties with product ions m/z 145 and 161, respectively. Metabolites identified at m/z 366 (B8, B9, B13), which was 16 Da higher than the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5,6,7,8,9], and this raises public health and social concerns. Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), SCBs are gaining popularity and are often abused as recreational drugs. The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples of both victims suggests that both substances played a role in the fatal outcom&lt;br&gt;&lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at https://cannabinoidsrc4f-adb.com/ least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.&lt;br&gt;Fig. &lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in humans. Drug discrimination is a well-known animal model of the subjective effects of drugs and correlates well with abuse liability (Young 2009; Horton et al. 2013). Assessment of abuse liability is based on several factors, including chemical structure, pharmacological mechanism of action, and finally, subjective and reinforcing behavioral effects (FDA, 2010; Swedberg, 2013).&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. </del>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Buy Jwh-210 at USA K2 INCENSE STORE </del>and <del class="diffchange diffchange-inline">enjoy premium quality</del>, <del class="diffchange diffchange-inline">flexible quantities, and fast, secure shipping</del>. <del class="diffchange diffchange-inline">Fast shipping and pure product</del>-<del class="diffchange diffchange-inline">highly recommended for anyone needing quality incense ingredients</del>.<del class="diffchange diffchange-inline">&quot; 🌟🌟🌟🌟🌟 You can buy jwh-210 online </del>in <del class="diffchange diffchange-inline">quantities of [https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/ https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/] 10g</del>, <del class="diffchange diffchange-inline">30g</del>, <del class="diffchange diffchange-inline">50g</del>, <del class="diffchange diffchange-inline">100g</del>, <del class="diffchange diffchange-inline">150g</del>, and <del class="diffchange diffchange-inline">200g at USA K2 INCENSE STORE </del>for <del class="diffchange diffchange-inline">premium quality </del>and <del class="diffchange diffchange-inline">discreet shipping</del>. <del class="diffchange diffchange-inline">In some areas, it </del>is <del class="diffchange diffchange-inline">classified as a controlled substance, while </del>in <del class="diffchange diffchange-inline">others, it may be legal for research or incense use</del>. The <del class="diffchange diffchange-inline">legal status </del>of <del class="diffchange diffchange-inline">jwh</del>-<del class="diffchange diffchange-inline">210 varies by country </del>and <del class="diffchange diffchange-inline">region</del>.&lt;br&gt; <del class="diffchange diffchange-inline">Key Features and Specifications to Evaluate </del>&lt;br&gt;<del class="diffchange diffchange-inline">Higher prices often reflect rigorous quality control rather than markup alone. This compound </del>is <del class="diffchange diffchange-inline">appropriate only </del>for <del class="diffchange diffchange-inline">authorized professionals conducting lawful research or analysis</del>. <del class="diffchange diffchange-inline">For legitimate applications</del>, <del class="diffchange diffchange-inline">only fully characterized, independently tested JWH-210 </del>https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">should be considered</del>.&lt;br&gt; <del class="diffchange diffchange-inline">How to Choose Powder JWH-210 </del>&lt;br&gt;<del class="diffchange diffchange-inline">When learning how to choose powder JWH</del>-<del class="diffchange diffchange-inline">210</del>, <del class="diffchange diffchange-inline">the most critical factor is verifying high chemical purity (≥98%) from </del>a <del class="diffchange diffchange-inline">reputable supplier </del>with <del class="diffchange diffchange-inline">independent lab testing</del>. <del class="diffchange diffchange-inline">We also demonstrated that JWH-210 administration resulted in the decrease </del>of <del class="diffchange diffchange-inline">expression levels </del>of <del class="diffchange diffchange-inline">T</del>-<del class="diffchange diffchange-inline">cell activator including Cd3e</del>, <del class="diffchange diffchange-inline">Cd3g</del>, <del class="diffchange diffchange-inline">Cd74p31</del>, and <del class="diffchange diffchange-inline">Cd74p41</del>, <del class="diffchange diffchange-inline">while JWH-030 increased Cd3g levels</del>. <del class="diffchange diffchange-inline">JWH-210 </del>(10 mg/kg, <del class="diffchange diffchange-inline">3 days</del>, <del class="diffchange diffchange-inline">i</del>.<del class="diffchange diffchange-inline">p.) </del>is <del class="diffchange diffchange-inline">more likely to have cytotoxicity and reduce lymphoid organ weight than JWH</del>-<del class="diffchange diffchange-inline">030 of ICR mice in vivo</del>. <del class="diffchange diffchange-inline">Users are expected </del>to <del class="diffchange diffchange-inline">handle </del>the <del class="diffchange diffchange-inline">compound in accordance with all applicable regulations </del>and <del class="diffchange diffchange-inline">safety guidelines within their jurisdiction</del>. <del class="diffchange diffchange-inline">It is important to note that </del>JWH-<del class="diffchange diffchange-inline">210 Chemical Powder is intended strictly for research </del>and <del class="diffchange diffchange-inline">laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramount.&lt;br&gt; Is </del>JWH-210 <del class="diffchange diffchange-inline">Legal? &lt;br&gt;A total </del>of <del class="diffchange diffchange-inline">2 </del>and <del class="diffchange diffchange-inline">3 methamphetamine treated </del>mice <del class="diffchange diffchange-inline">fell from the spinning rod 30 min and 2 hr after the administration, respectively</del>. <del class="diffchange diffchange-inline">After the first injection</del>, <del class="diffchange diffchange-inline">6 mice of the positive control group (methamphetamine</del>, 5 mg/kg<del class="diffchange diffchange-inline">, i</del>.<del class="diffchange diffchange-inline">p.) showed loss </del>of <del class="diffchange diffchange-inline">traction</del>, <del class="diffchange diffchange-inline">of which 4 showed tremor</del>. <del class="diffchange diffchange-inline">Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). <ins class="diffchange diffchange-inline">4F ADB </ins>Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 </ins>and <ins class="diffchange diffchange-inline">2.49 g/L</ins>, <ins class="diffchange diffchange-inline">respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No</ins>.<ins class="diffchange diffchange-inline">R (99)3 of the Council of Europe on medico</ins>-<ins class="diffchange diffchange-inline">legal autopsies</ins>. <ins class="diffchange diffchange-inline">Elegans demonstrated the ability to form all of the </ins>in-<ins class="diffchange diffchange-inline">vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs</ins>. <ins class="diffchange diffchange-inline">Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in</ins>-<ins class="diffchange diffchange-inline">vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio</ins>. <ins class="diffchange diffchange-inline">Moreover, genetic makeup</ins>, <ins class="diffchange diffchange-inline">physiological conditions (age</ins>, <ins class="diffchange diffchange-inline">gender 4F ADB and ethnicity)</ins>, <ins class="diffchange diffchange-inline">environmental influences (diet) and pathological factors (liver diseases</ins>, <ins class="diffchange diffchange-inline">diabetes</ins>, and <ins class="diffchange diffchange-inline">obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias </ins>for <ins class="diffchange diffchange-inline">each metabolite.&lt;br&gt;Data concerning the combined effects of SCRAs </ins>and <ins class="diffchange diffchange-inline">other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult </ins>. <ins class="diffchange diffchange-inline">The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol </ins>is <ins class="diffchange diffchange-inline">present </ins>in <ins class="diffchange diffchange-inline">the blood</ins>. The <ins class="diffchange diffchange-inline">victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism </ins>of <ins class="diffchange diffchange-inline">synthetic cannabinoid 4F-MDMB-BINACA via high</ins>-<ins class="diffchange diffchange-inline">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes </ins>and <ins class="diffchange diffchange-inline">confirmed using urine samples</ins>. <ins class="diffchange diffchange-inline">This article does not contain any studies with human participants or animals performed by any of the author&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">All of the compounds tested in the present study depressed locomotor activity as </ins>is <ins class="diffchange diffchange-inline">typical </ins>for <ins class="diffchange diffchange-inline">other synthetic cannabinoids (see review by Wiley et al</ins>., <ins class="diffchange diffchange-inline">2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [</ins>https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">4F ADB] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2</ins>.<ins class="diffchange diffchange-inline">5 h following 1 mg/k</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">4. Drugs &lt;br&gt;Short</ins>-<ins class="diffchange diffchange-inline">onset</ins>, <ins class="diffchange diffchange-inline">short-acting compounds have </ins>a <ins class="diffchange diffchange-inline">greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions </ins>with <ins class="diffchange diffchange-inline">other drugs</ins>. <ins class="diffchange diffchange-inline">The duration </ins>of <ins class="diffchange diffchange-inline">action </ins>of <ins class="diffchange diffchange-inline">the synthetic cannabinoids tested using the 8</ins>-<ins class="diffchange diffchange-inline">h protocol have varied widely</ins>, <ins class="diffchange diffchange-inline">with some producing a duration of action no longer than 1 h</ins>, <ins class="diffchange diffchange-inline">others producing a duration of action between 1–2 h</ins>, and <ins class="diffchange diffchange-inline">others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al.</ins>, <ins class="diffchange diffchange-inline">2017)</ins>. <ins class="diffchange diffchange-inline">Average horizontal activity counts/10 min as a function of time </ins>(10 <ins class="diffchange diffchange-inline">min bins) and dose. Depressant effects of 1.33 </ins>mg/kg <ins class="diffchange diffchange-inline">were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;In the present study</ins>, <ins class="diffchange diffchange-inline">we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation</ins>, <ins class="diffchange diffchange-inline">and water-maze test for learning/memory evaluation</ins>. <ins class="diffchange diffchange-inline">Known for its stability and consistent composition, this compound </ins>is <ins class="diffchange diffchange-inline">frequently utilized by professionals seeking reliable materials for laboratory</ins>-<ins class="diffchange diffchange-inline">based analytical studies</ins>. <ins class="diffchange diffchange-inline">In this study, histopathological evaluation was performed </ins>to <ins class="diffchange diffchange-inline">confirm </ins>the <ins class="diffchange diffchange-inline">possibility of neurotoxicity of the tested substances by hematoxylin </ins>and <ins class="diffchange diffchange-inline">eosin staining method from collected brain samples</ins>. <ins class="diffchange diffchange-inline">In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (</ins>JWH-<ins class="diffchange diffchange-inline">081 </ins>and JWH-210<ins class="diffchange diffchange-inline">) through observation </ins>of <ins class="diffchange diffchange-inline">various behavioral changes </ins>and <ins class="diffchange diffchange-inline">analysis of histopathological changes using experimental </ins>mice <ins class="diffchange diffchange-inline">with various doses (0</ins>.<ins class="diffchange diffchange-inline">1</ins>, <ins class="diffchange diffchange-inline">1</ins>, 5 mg/kg<ins class="diffchange diffchange-inline">)</ins>. <ins class="diffchange diffchange-inline">Selecting powder JWH-210 demands careful evaluation </ins>of <ins class="diffchange diffchange-inline">purity</ins>, <ins class="diffchange diffchange-inline">legality, and supplier credibility</ins>. <ins class="diffchange diffchange-inline">Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28431:rev-28644 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28431&oldid=prev 2026-06-01T17:20:47Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:20 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Tremors were observed in mice 30 minutes following 1 mg</del>/<del class="diffchange diffchange-inline">kg AMB</del>-<del class="diffchange diffchange-inline">FUBINACA in </del>the <del class="diffchange diffchange-inline">present study. Pretreatment times </del>and <del class="diffchange diffchange-inline">dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice</del>. <del class="diffchange diffchange-inline">Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg</del>/<del class="diffchange diffchange-inline">kg </del>(<del class="diffchange diffchange-inline">Gatch et al.</del>, <del class="diffchange diffchange-inline">2014</del>), <del class="diffchange diffchange-inline">whereas </del>the <del class="diffchange diffchange-inline">potency of a recent set was 0.09±0.03 mg/kg </del>(<del class="diffchange diffchange-inline">Gatch et al</del>., <del class="diffchange diffchange-inline">2018)</del>, and the <del class="diffchange diffchange-inline">potency </del>of <del class="diffchange diffchange-inline">the current set is 0.05±0.01 mg/kg. Short-onset</del>, <del class="diffchange diffchange-inline">short</del>-<del class="diffchange diffchange-inline">acting compounds have a greater abuse liability</del>, and <del class="diffchange diffchange-inline">long</del>-<del class="diffchange diffchange-inline">acting compounds pose problems of long</del>-<del class="diffchange diffchange-inline">acting adverse effects </del>and <del class="diffchange diffchange-inline">interactions with other drugs. The duration </del>of <del class="diffchange diffchange-inline">action </del>of the synthetic cannabinoids <del class="diffchange diffchange-inline">tested using the 8-h protocol have varied widely, with some producing a duration of action no longer </del>than <del class="diffchange diffchange-inline">1 h</del>, <del class="diffchange diffchange-inline">others producing a duration of action between 1–2 h</del>, and <del class="diffchange diffchange-inline">others lasting more than 2 h. There seems to be </del>a <del class="diffchange diffchange-inline">trend of newer synthetic cannabinoids being more potent than earlier </del>compound&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Our findings revealed that both victims consumed large amounts </del>of <del class="diffchange diffchange-inline">alcohol preceding their deaths (blood alcohol concentrations (BAC) </del>were <del class="diffchange diffchange-inline">2</del>.<del class="diffchange diffchange-inline">11 and 2</del>.<del class="diffchange diffchange-inline">49 g</del>/<del class="diffchange diffchange-inline">L</del>, <del class="diffchange diffchange-inline">respectively). Forensic autopsy </del>of <del class="diffchange diffchange-inline">both victims was performed four days after </del>the <del class="diffchange diffchange-inline">time </del>of <del class="diffchange diffchange-inline">death following </del>the <del class="diffchange diffchange-inline">Recommendation No</del>.<del class="diffchange diffchange-inline">R </del>(<del class="diffchange diffchange-inline">99</del>)<del class="diffchange diffchange-inline">3 of the Council of Europe </del>on <del class="diffchange diffchange-inline">medico-legal autopsies. Elegans demonstrated the ability to form all of </del>the in<del class="diffchange diffchange-inline">-vivo metabolites and </del>has <del class="diffchange diffchange-inline">the potential to be </del>used as <del class="diffchange diffchange-inline">a complementary model to predict </del>and <del class="diffchange diffchange-inline">characterize human metabolites, </del>as <del class="diffchange diffchange-inline">well </del>as <del class="diffchange diffchange-inline">identifying possible drug toxicities for emerging SCBs</del>. <del class="diffchange diffchange-inline">Thus, identification </del>of the <del class="diffchange diffchange-inline">relevant urinary markers </del>was <del class="diffchange diffchange-inline">based primarily upon </del>the <del class="diffchange diffchange-inline">prevalence </del>of the in-<del class="diffchange diffchange-inline">vivo metabolites instead </del>of the <del class="diffchange diffchange-inline">metabolites ranking that was </del>based <del class="diffchange diffchange-inline">upon % peak area abundance ratio. Moreover</del>, <del class="diffchange diffchange-inline">genetic makeup</del>, <del class="diffchange diffchange-inline">physiological conditions (age</del>, <del class="diffchange diffchange-inline">gender adb butinaca </del>and <del class="diffchange diffchange-inline">ethnicity)</del>, <del class="diffchange diffchange-inline">environmental influences (diet) </del>and <del class="diffchange diffchange-inline">pathological factors </del>(<del class="diffchange diffchange-inline">liver diseases</del>, <del class="diffchange diffchange-inline">diabetes</del>, <del class="diffchange diffchange-inline">and obesity</del>) <del class="diffchange diffchange-inline">would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data concerning </del>the <del class="diffchange diffchange-inline">combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level </del>(<del class="diffchange diffchange-inline">0</del>.<del class="diffchange diffchange-inline">37–4</del>.<del class="diffchange diffchange-inline">1 ng/mL according </del>to the <del class="diffchange diffchange-inline">reported cases) in cases in which 1</del>.<del class="diffchange diffchange-inline">5–2.5 g/L </del>of <del class="diffchange diffchange-inline">ethanol is present in </del>the <del class="diffchange diffchange-inline">blood. The victims were brothers who were both found deceased after consuming 4F-MDMB</del>-<del class="diffchange diffchange-inline">BINACA </del>and <del class="diffchange diffchange-inline">ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F</del>-<del class="diffchange diffchange-inline">MDMB-BINACA via high-resolution mass spectrometry assessed </del>in <del class="diffchange diffchange-inline">cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author</del>&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;<del class="diffchange diffchange-inline">These synthetic cannabinoids act directly at cannabinoid CB1 </del>and <del class="diffchange diffchange-inline">CB2 receptors as does Δ9-tetrahydrocannabinol (</del>Δ9-THC<del class="diffchange diffchange-inline">) found </del>in <del class="diffchange diffchange-inline">marijuana</del>, <del class="diffchange diffchange-inline">but have different chemical structures unrelated to Δ9</del>-<del class="diffchange diffchange-inline">THC</del>, <del class="diffchange diffchange-inline">different metabolism</del>, <del class="diffchange diffchange-inline">and often greater toxicity </del>(<del class="diffchange diffchange-inline">Fantegrossi et al</del>.<del class="diffchange diffchange-inline">, 2014)</del>. <del class="diffchange diffchange-inline">Discriminative stimulus effects </del>were <del class="diffchange diffchange-inline">tested in rats trained </del>to <del class="diffchange diffchange-inline">discriminate Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol </del>(<del class="diffchange diffchange-inline">3 mg/kg</del>, <del class="diffchange diffchange-inline">30-min pretreatment</del>). <del class="diffchange diffchange-inline">5F-MDMB-PINACA </del>(<del class="diffchange diffchange-inline">also known as 5F-ADB</del>, <del class="diffchange diffchange-inline">5F-ADB-PINACA</del>)<del class="diffchange diffchange-inline">, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, </del>and <del class="diffchange diffchange-inline">AMB-FUBINACA </del>(<del class="diffchange diffchange-inline">also known as FUB-AMB, MMB-FUBINACA</del>) <del class="diffchange diffchange-inline">were tested </del>for <del class="diffchange diffchange-inline">in vivo cannabinoid-like effects </del>to <del class="diffchange diffchange-inline">assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">In general</del>, <del class="diffchange diffchange-inline">the locomotor depressant </del>and <del class="diffchange diffchange-inline">discriminative stimulus effects </del>[https://cannabinoidsrc4f-adb.com/ adb <del class="diffchange diffchange-inline">butinaca</del>] <del class="diffchange diffchange-inline">have been observed </del>at <del class="diffchange diffchange-inline">doses that do not produce adverse effects</del>, <del class="diffchange diffchange-inline">although tremors were observed upon handling </del>in <del class="diffchange diffchange-inline">mice that received JWH</del>-210 <del class="diffchange diffchange-inline">(Gatch et al</del>., <del class="diffchange diffchange-inline">2016)</del>, <del class="diffchange diffchange-inline">and 5F</del>-<del class="diffchange diffchange-inline">AMB produced sustained vocalization and convulsions in rats (Gatch et al</del>., <del class="diffchange diffchange-inline">2018</del>). <del class="diffchange diffchange-inline">All of the synthetic cannabinoids tested </del>in the <del class="diffchange diffchange-inline">present study fully substituted for the discriminative stimulus effects </del>of <del class="diffchange diffchange-inline">Δ9</del>-<del class="diffchange diffchange-inline">THC. Subsequently</del>, <del class="diffchange diffchange-inline">a one</del>-<del class="diffchange diffchange-inline">way analysis of variance was conducted on horizontal activity counts for the 30</del>-<del class="diffchange diffchange-inline">min period of maximal effect</del>, and <del class="diffchange diffchange-inline">planned comparisons were conducted for each dose against the vehicle control using single degree</del>-of<del class="diffchange diffchange-inline">-freedom F tests</del>. <del class="diffchange diffchange-inline">A two-way analysis of variance, </del>with <del class="diffchange diffchange-inline">dose as a between groups factor </del>and <del class="diffchange diffchange-inline">time as a </del>within <del class="diffchange diffchange-inline">subject factor, was conducted on horizontal activity counts/10 min interval</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gatch </del>&lt;br&gt;<del class="diffchange diffchange-inline">Duration </del>of the <del class="diffchange diffchange-inline">locomotor depression increased over dose from </del>30 min <del class="diffchange diffchange-inline">following 0.1 mg/kg to </del>2.5 <del class="diffchange diffchange-inline">h following 1 </del>mg/kg. <del class="diffchange diffchange-inline">Substantial depressant effects were observed within the first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression was observed between 0–30 min following administration</del>. <del class="diffchange diffchange-inline">Tremors </del>were <del class="diffchange diffchange-inline">observed 30 minutes following 1 mg/kg AMB-FUBINACA </del>in <del class="diffchange diffchange-inline">3 </del>of <del class="diffchange diffchange-inline">8 mice (data not shown)</del>. <del class="diffchange diffchange-inline">Substantial depressant effects </del>were <del class="diffchange diffchange-inline">observed within </del>the <del class="diffchange diffchange-inline">first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at </del>the <del class="diffchange diffchange-inline">highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function </del>of <del class="diffchange diffchange-inline">time (0–4 h) and dose of Δ9-TH</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Similarly, precursor ion identified at m/z 380 (B19/B21, B23</ins>/<ins class="diffchange diffchange-inline">B25) was 16 Da higher than the 4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA, indicating monohydroxylation at </ins>the <ins class="diffchange diffchange-inline">butyl side chain (B19/B21) and indazole (B23/B25) moieties with product ions m/z 145 </ins>and <ins class="diffchange diffchange-inline">161, respectively</ins>. <ins class="diffchange diffchange-inline">Metabolites identified at m</ins>/<ins class="diffchange diffchange-inline">z 366 </ins>(<ins class="diffchange diffchange-inline">B8, B9</ins>, <ins class="diffchange diffchange-inline">B13</ins>), <ins class="diffchange diffchange-inline">which was 16 Da higher than </ins>the <ins class="diffchange diffchange-inline">4F-MDMB-BINACA ester hydrolysis metabolite </ins>(<ins class="diffchange diffchange-inline">B22), confirmed monohydroxylation upon ester hydrolysis</ins>. <ins class="diffchange diffchange-inline">Death involving these drugs have been reported [5,6</ins>,<ins class="diffchange diffchange-inline">7,8,9]</ins>, and <ins class="diffchange diffchange-inline">this raises public health and social concerns. Due to their similar physiological effects to </ins>the <ins class="diffchange diffchange-inline">principal psychoactive component </ins>of <ins class="diffchange diffchange-inline">cannabis</ins>, <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">tetrahydrocannabinol (THC)</ins>, <ins class="diffchange diffchange-inline">SCBs are gaining popularity </ins>and <ins class="diffchange diffchange-inline">are often abused as recreational drugs. The fact that similar 4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA </ins>and <ins class="diffchange diffchange-inline">ethanol concentrations were detected in the postmortem blood samples </ins>of <ins class="diffchange diffchange-inline">both victims suggests that both substances played a role in the fatal outcom&lt;br&gt;&lt;br&gt;There is indication that at least some </ins>of the <ins class="diffchange diffchange-inline">first-generation </ins>synthetic cannabinoids <ins class="diffchange diffchange-inline">act at receptors other </ins>than <ins class="diffchange diffchange-inline">cannabinoid CB1 and CB2 (Wiley et al.</ins>, <ins class="diffchange diffchange-inline">2016)</ins>, and a compound <ins class="diffchange diffchange-inline">from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Effects </ins>of <ins class="diffchange diffchange-inline">individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data </ins>were <ins class="diffchange diffchange-inline">analyzed by one-way repeated-measure analysis of variance</ins>. <ins class="diffchange diffchange-inline">Percent drug-appropriate responding was shown only if at https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com</ins>/ <ins class="diffchange diffchange-inline">least three rats completed the first fixed ratio</ins>, <ins class="diffchange diffchange-inline">whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;Inclusion in an NLM database does not imply endorsement </ins>of<ins class="diffchange diffchange-inline">, or agreement with, the contents by NLM or </ins>the <ins class="diffchange diffchange-inline">National Institutes </ins>of <ins class="diffchange diffchange-inline">Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under </ins>the <ins class="diffchange diffchange-inline">Psychoactive Substances Act 2016</ins>. <ins class="diffchange diffchange-inline">The corresponding indole core analogue, 4F-MDMB-BICA </ins>(<ins class="diffchange diffchange-inline">4F-MDMB-BUTICA</ins>)<ins class="diffchange diffchange-inline">, has also been widely sold as a designer drug by chemical providers </ins>on the <ins class="diffchange diffchange-inline">internet, first being identified </ins>in <ins class="diffchange diffchange-inline">May 2020. It </ins>has <ins class="diffchange diffchange-inline">been </ins>used as <ins class="diffchange diffchange-inline">an active ingredient in synthetic cannabis products </ins>and <ins class="diffchange diffchange-inline">sold </ins>as <ins class="diffchange diffchange-inline">a designer drug since late 2018. 4F-MDMB-BINACA (also known </ins>as <ins class="diffchange diffchange-inline">MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.&lt;br&gt;Fig. &lt;br&gt;&lt;br&gt;4</ins>. <ins class="diffchange diffchange-inline">Drugs &lt;br&gt;The purpose </ins>of the <ins class="diffchange diffchange-inline">present study </ins>was <ins class="diffchange diffchange-inline">to assess </ins>the <ins class="diffchange diffchange-inline">abuse liability </ins>of <ins class="diffchange diffchange-inline">5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability </ins>the <ins class="diffchange diffchange-inline">likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking </ins>in <ins class="diffchange diffchange-inline">humans. Drug discrimination is a well</ins>-<ins class="diffchange diffchange-inline">known animal model </ins>of the <ins class="diffchange diffchange-inline">subjective effects of drugs and correlates well with abuse liability (Young 2009; Horton et al. 2013). Assessment of abuse liability is </ins>based <ins class="diffchange diffchange-inline">on several factors</ins>, <ins class="diffchange diffchange-inline">including chemical structure</ins>, <ins class="diffchange diffchange-inline">pharmacological mechanism of action</ins>, and <ins class="diffchange diffchange-inline">finally</ins>, <ins class="diffchange diffchange-inline">subjective </ins>and <ins class="diffchange diffchange-inline">reinforcing behavioral effects </ins>(<ins class="diffchange diffchange-inline">FDA</ins>, <ins class="diffchange diffchange-inline">2010; Swedberg</ins>, <ins class="diffchange diffchange-inline">2013</ins>).&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;Such decrease remained 2 hr after </ins>the <ins class="diffchange diffchange-inline">administration </ins>(<ins class="diffchange diffchange-inline">Table 4)</ins>. <ins class="diffchange diffchange-inline">In locomotor activity, methamphetamine treated group showed approximately 4</ins>.<ins class="diffchange diffchange-inline">2 times increase compared </ins>to the <ins class="diffchange diffchange-inline">negative control treated group</ins>. <ins class="diffchange diffchange-inline">Change </ins>of <ins class="diffchange diffchange-inline">body weight following </ins>the <ins class="diffchange diffchange-inline">treatments with JWH</ins>-<ins class="diffchange diffchange-inline">081 </ins>and <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 </ins>in <ins class="diffchange diffchange-inline">mic</ins>&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;<ins class="diffchange diffchange-inline">Each training session lasted a maximum of 10 min, </ins>and <ins class="diffchange diffchange-inline">the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or </ins>Δ9-THC <ins class="diffchange diffchange-inline">and were subsequently placed </ins>in <ins class="diffchange diffchange-inline">the behavior-testing chambers</ins>, <ins class="diffchange diffchange-inline">where food (45-mg food pellets; Bio</ins>-<ins class="diffchange diffchange-inline">Serve</ins>, <ins class="diffchange diffchange-inline">Frenchtown</ins>, <ins class="diffchange diffchange-inline">NJ) was available as a reinforcer for every ten responses </ins>(<ins class="diffchange diffchange-inline">FR10) on a designated injection appropriate lever</ins>. <ins class="diffchange diffchange-inline">A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active</ins>. <ins class="diffchange diffchange-inline">Each dose range included doses that </ins>were <ins class="diffchange diffchange-inline">without effect to those producing at least 50% depression compared </ins>to <ins class="diffchange diffchange-inline">vehicle control. Twenty-four male Sprague</ins>-<ins class="diffchange diffchange-inline">Dawley rats were obtained from Envigo </ins>(<ins class="diffchange diffchange-inline">Houston</ins>, <ins class="diffchange diffchange-inline">TX</ins>). <ins class="diffchange diffchange-inline">Male ND4 Swiss–Webster mice were obtained from Envigo </ins>(<ins class="diffchange diffchange-inline">Houston</ins>, <ins class="diffchange diffchange-inline">TX</ins>) <ins class="diffchange diffchange-inline">at approximately 8 weeks of age </ins>and <ins class="diffchange diffchange-inline">maintained in the University of North Texas Health Science Center </ins>(<ins class="diffchange diffchange-inline">UNTHSC</ins>) <ins class="diffchange diffchange-inline">animal facility </ins>for <ins class="diffchange diffchange-inline">two weeks prior </ins>to <ins class="diffchange diffchange-inline">testin</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Buy Jwh-210 at USA K2 INCENSE STORE and enjoy premium quality, flexible quantities, and fast</ins>, <ins class="diffchange diffchange-inline">secure shipping. Fast shipping </ins>and <ins class="diffchange diffchange-inline">pure product-highly recommended for anyone needing quality incense ingredients.&quot; 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities of </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">https://cannabinoidsrc4f-</ins>adb<ins class="diffchange diffchange-inline">.com/</ins>] <ins class="diffchange diffchange-inline">10g, 30g, 50g, 100g, 150g, and 200g </ins>at <ins class="diffchange diffchange-inline">USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified as a controlled substance</ins>, <ins class="diffchange diffchange-inline">while </ins>in <ins class="diffchange diffchange-inline">others, it may be legal for research or incense use. The legal status of jwh</ins>-210 <ins class="diffchange diffchange-inline">varies by country and region.&lt;br&gt; Key Features and Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis</ins>. <ins class="diffchange diffchange-inline">For legitimate applications</ins>, <ins class="diffchange diffchange-inline">only fully characterized</ins>, <ins class="diffchange diffchange-inline">independently tested JWH-210 https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com/ should be considered</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt; How to Choose Powder JWH-210 &lt;br&gt;When learning how to choose powder JWH-210</ins>, <ins class="diffchange diffchange-inline">the most critical factor is verifying high chemical purity (≥98%</ins>) <ins class="diffchange diffchange-inline">from a reputable supplier with independent lab testing</ins>. <ins class="diffchange diffchange-inline">We also demonstrated that JWH-210 administration resulted </ins>in the <ins class="diffchange diffchange-inline">decrease of expression levels </ins>of <ins class="diffchange diffchange-inline">T</ins>-<ins class="diffchange diffchange-inline">cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41</ins>, <ins class="diffchange diffchange-inline">while JWH</ins>-<ins class="diffchange diffchange-inline">030 increased Cd3g levels. JWH</ins>-<ins class="diffchange diffchange-inline">210 (10 mg/kg, 3 days</ins>, <ins class="diffchange diffchange-inline">i.p.) is more likely to have cytotoxicity </ins>and <ins class="diffchange diffchange-inline">reduce lymphoid organ weight than JWH</ins>-<ins class="diffchange diffchange-inline">030 </ins>of <ins class="diffchange diffchange-inline">ICR mice in vivo</ins>. <ins class="diffchange diffchange-inline">Users are expected to handle the compound in accordance </ins>with <ins class="diffchange diffchange-inline">all applicable regulations </ins>and <ins class="diffchange diffchange-inline">safety guidelines </ins>within <ins class="diffchange diffchange-inline">their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramount</ins>.&lt;br&gt; <ins class="diffchange diffchange-inline">Is JWH-210 Legal? </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">A total </ins>of <ins class="diffchange diffchange-inline">2 and 3 methamphetamine treated mice fell from </ins>the <ins class="diffchange diffchange-inline">spinning rod </ins>30 min <ins class="diffchange diffchange-inline">and </ins>2 <ins class="diffchange diffchange-inline">hr after the administration, respectively</ins>. <ins class="diffchange diffchange-inline">After the first injection, 6 mice of the positive control group (methamphetamine, </ins>5 mg/kg<ins class="diffchange diffchange-inline">, i</ins>.<ins class="diffchange diffchange-inline">p.) showed loss of traction</ins>, <ins class="diffchange diffchange-inline">of which 4 showed tremor</ins>. <ins class="diffchange diffchange-inline">Most of the abnormalities </ins>were <ins class="diffchange diffchange-inline">normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained </ins>in <ins class="diffchange diffchange-inline">methamphetamine treated animals after 2 hr </ins>of <ins class="diffchange diffchange-inline">administration</ins>. <ins class="diffchange diffchange-inline">Brain samples </ins>were <ins class="diffchange diffchange-inline">prepared from </ins>the <ins class="diffchange diffchange-inline">mice after </ins>the <ins class="diffchange diffchange-inline">last administration </ins>of <ins class="diffchange diffchange-inline">test substance</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28426:rev-28431 --> </table>

AlizaMoberg10 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28426&oldid=prev 2026-06-01T17:18:57Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:18 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Due to </del>the <del class="diffchange diffchange-inline">unknown toxicity </del>of <del class="diffchange diffchange-inline">newly emerging SCRAs</del>, <del class="diffchange diffchange-inline">forensic assessments </del>of <del class="diffchange diffchange-inline">cases involving these substances are challenging</del>. <del class="diffchange diffchange-inline">According to </del>the <del class="diffchange diffchange-inline">reported cases and reviews </del>of the <del class="diffchange diffchange-inline">scientific literature</del>, <del class="diffchange diffchange-inline">concurrent ethanol consumption should amplify the toxicity </del>of <del class="diffchange diffchange-inline">SCRAs</del>. The <del class="diffchange diffchange-inline">concentration </del>of <del class="diffchange diffchange-inline">4F</del>-<del class="diffchange diffchange-inline">MDMB-BINACA in the postmortem blood was 2.50 </del>and 2.<del class="diffchange diffchange-inline">34 ng/mL, and </del>blood alcohol <del class="diffchange diffchange-inline">concentration was </del>2.11 and 2.49 g/L, respectively. <del class="diffchange diffchange-inline">Two fatal cases are reported caused by simultaneous consumption </del>of <del class="diffchange diffchange-inline">4F-MDMB-BINACA and ethanol</del>.<del class="diffchange diffchange-inline">&lt;br&gt;Fig. 2. &lt;br&gt;The precursor ion m/z 396 </del>(<del class="diffchange diffchange-inline">B10, B12/B15</del>) <del class="diffchange diffchange-inline">was 32 Da higher than </del>the <del class="diffchange diffchange-inline">parent drug, 4F</del>-<del class="diffchange diffchange-inline">MDMB-BINACA, suggesting </del>the <del class="diffchange diffchange-inline">addition </del>of <del class="diffchange diffchange-inline">two hydroxy groups. All </del>the <del class="diffchange diffchange-inline">below explanations for transformations into </del>metabolites <del class="diffchange diffchange-inline">are based on </del>the <del class="diffchange diffchange-inline">data shown in Fig. Metabolites were identified according </del>to <del class="diffchange diffchange-inline">their precursor ions</del>, <del class="diffchange diffchange-inline">product ions</del>, <del class="diffchange diffchange-inline">and fragmentation patterns (Fig. 1). Traditional </del>in-vivo <del class="diffchange diffchange-inline">metabolism studies to generate human </del>metabolites of <del class="diffchange diffchange-inline">drugs relied heavily on </del>the <del class="diffchange diffchange-inline">use of whole animal model systems</del>, <del class="diffchange diffchange-inline">which are expensive</del>, <del class="diffchange diffchange-inline">limited by drug administration amount</del>, <del class="diffchange diffchange-inline">influenced by species variation </del>and <del class="diffchange diffchange-inline">faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation</del>, <del class="diffchange diffchange-inline">N-dealkylation</del>, <del class="diffchange diffchange-inline">monohydroxylation </del>and <del class="diffchange diffchange-inline">oxidative defluorination with </del>further <del class="diffchange diffchange-inline">oxidation </del>to <del class="diffchange diffchange-inline">butanoic acid</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 1. &lt;br&gt;This outcome was anticipated since CES-mediated hydrolysis is commonly 4F ADB reported as </del>the <del class="diffchange diffchange-inline">major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides </del>and <del class="diffchange diffchange-inline">sulfate metabolites have been reported with </del>other <del class="diffchange diffchange-inline">SCBs where C. From these three samples</del>, <del class="diffchange diffchange-inline">sample 2 contained only an ester hydrolysis metabolite (m/z 350)</del>. <del class="diffchange diffchange-inline">Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m</del>/<del class="diffchange diffchange-inline">z 362) and monohydroxylation at tert-leucine moiety </del>(<del class="diffchange diffchange-inline">B8, m</del>/<del class="diffchange diffchange-inline">z 366</del>) <del class="diffchange diffchange-inline">metabolites were found </del>in <del class="diffchange diffchange-inline">16/20 urine samples (Table 2)</del>. <del class="diffchange diffchange-inline">A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C</del>. <del class="diffchange diffchange-inline">The product ion detected at m</del>/<del class="diffchange diffchange-inline">z 235, indicating loss </del>of <del class="diffchange diffchange-inline">sulfate, confirmed </del>the <del class="diffchange diffchange-inline">identity of the sulfation metabolite</del>.<del class="diffchange diffchange-inline">&lt;br&gt;Fungus C. elegans &lt;br&gt;Concentrations of </del>4F-MDMB-BINACA <del class="diffchange diffchange-inline">in the postmortem blood samples were 2.50 </del>and <del class="diffchange diffchange-inline">2</del>.<del class="diffchange diffchange-inline">34 ng/mL, which are in line with published data</del>. <del class="diffchange diffchange-inline">Although the lethal dose </del>of 4F-MDMB-BINACA <del class="diffchange diffchange-inline">is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA</del>-<del class="diffchange diffchange-inline">related cases </del>in <del class="diffchange diffchange-inline">which the deceased suffered from heart disease</del>, <del class="diffchange diffchange-inline">the SCRA concentration in the postmortem blood was less than 1 ng/mL </del>. <del class="diffchange diffchange-inline">Concentrations </del>of <del class="diffchange diffchange-inline">SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) </del>and <del class="diffchange diffchange-inline">positive </del>(<del class="diffchange diffchange-inline">methamphetamine</del>) <del class="diffchange diffchange-inline">controls. After the last administration</del>, <del class="diffchange diffchange-inline">the first trial was performed. Morris water maze test was performed </del>to <del class="diffchange diffchange-inline">evaluate the changes of learning and memory function through administration of the test substances. Generally</del>, <del class="diffchange diffchange-inline">neurotoxicity of a substance is evaluated by animal behavioral aspects</del>, <del class="diffchange diffchange-inline">i.e. functional observation battery </del>(<del class="diffchange diffchange-inline">FOB) tests (O’Callaghan </del>et al., 2014). <del class="diffchange diffchange-inline">Our results suggest that JWH</del>-<del class="diffchange diffchange-inline">081 </del>and <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">210 may </del>[https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">4F ADB</del>] <del class="diffchange diffchange-inline">be neurotoxic substances through changing neuronal cell damages</del>, <del class="diffchange diffchange-inline">especially </del>in <del class="diffchange diffchange-inline">the core shell part of nucleus accumbens.&lt;br&gt;About Powder </del>JWH-<del class="diffchange diffchange-inline">2&lt;br&gt;&lt;br&gt;&lt;br&gt;High resolution mass spectrometry such as LC</del>-<del class="diffchange diffchange-inline">QTOF-MS allows the detection </del>and <del class="diffchange diffchange-inline">identification </del>of <del class="diffchange diffchange-inline">a broad spectrum </del>of <del class="diffchange diffchange-inline">recreational drugs</del>, <del class="diffchange diffchange-inline">including new psychoactive substances. A point</del>-of<del class="diffchange diffchange-inline">-care drugs of abuse (DOA) test </del>was <del class="diffchange diffchange-inline">initially performed </del>on the <del class="diffchange diffchange-inline">urine </del>of the <del class="diffchange diffchange-inline">patient. He confirmed drinking 750 ml energy drink without any further consumption of food and </del>using <del class="diffchange diffchange-inline">an e</del>-<del class="diffchange diffchange-inline">cigarette from Gaziantep, Turkey 10 seconds before the onset </del>of <del class="diffchange diffchange-inline">his first symptoms</del>. <del class="diffchange diffchange-inline">He usually smokes a pack </del>of <del class="diffchange diffchange-inline">cigarettes </del>a <del class="diffchange diffchange-inline">day </del>and <del class="diffchange diffchange-inline">sometimes smokes e-cigarettes. Combined with non-specific</del>, <del class="diffchange diffchange-inline">transient symptoms, clinical recognition of SCRA intoxication is challenging </del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availability </del>&lt;br&gt;<del class="diffchange diffchange-inline">The intensity is plotted against </del>the <del class="diffchange diffchange-inline">retention time for both chromatograms</del>, <del class="diffchange diffchange-inline">demonstrating the 4F ADB presence </del>and <del class="diffchange diffchange-inline">elution profiles of nicotine and ADB</del>-<del class="diffchange diffchange-inline">BUTINACA </del>in <del class="diffchange diffchange-inline">the analysed vape liquid sample. LC-QTOF-MS Chromatograms </del>of <del class="diffchange diffchange-inline">Nicotine </del>(<del class="diffchange diffchange-inline">Top</del>) and <del class="diffchange diffchange-inline">ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient</del>. <del class="diffchange diffchange-inline">The LC-QTOF-MS analysis showed that </del>the <del class="diffchange diffchange-inline">e-liquid contained nicotine and ADB-BUTINACA </del>(<del class="diffchange diffchange-inline">Fig</del>. <del class="diffchange diffchange-inline">1</del>). <del class="diffchange diffchange-inline">Because the point-</del>of<del class="diffchange diffchange-inline">-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole </del>time<del class="diffchange diffchange-inline">-of-flight mass spectrometry </del>(<del class="diffchange diffchange-inline">LC-QTOF-MS</del>) <del class="diffchange diffchange-inline">on the Waters™ Xevo G3 QTOF MS system. After eating a light meal </del>and <del class="diffchange diffchange-inline">drinking caffeinated sports drinks at the ER, the nausea complaints </del>of <del class="diffchange diffchange-inline">the patient were reduced and the patient was discharged hom</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of </ins>the <ins class="diffchange diffchange-inline">discriminative stimulus effects </ins>of <ins class="diffchange diffchange-inline">early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014)</ins>, <ins class="diffchange diffchange-inline">whereas the potency </ins>of <ins class="diffchange diffchange-inline">a recent set was 0.09±0.03 mg/kg (Gatch et al</ins>.<ins class="diffchange diffchange-inline">, 2018), and </ins>the <ins class="diffchange diffchange-inline">potency </ins>of the <ins class="diffchange diffchange-inline">current set is 0.05±0.01 mg/kg. Short-onset</ins>, <ins class="diffchange diffchange-inline">short-acting compounds have a greater abuse liability, and long-acting compounds pose problems </ins>of <ins class="diffchange diffchange-inline">long-acting adverse effects and interactions with other drugs</ins>. The <ins class="diffchange diffchange-inline">duration of action </ins>of <ins class="diffchange diffchange-inline">the synthetic cannabinoids tested using the 8</ins>-<ins class="diffchange diffchange-inline">h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, </ins>and <ins class="diffchange diffchange-inline">others lasting more than </ins>2 <ins class="diffchange diffchange-inline">h</ins>. <ins class="diffchange diffchange-inline">There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound&lt;br&gt;&lt;br&gt;&lt;br&gt;Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (</ins>blood alcohol <ins class="diffchange diffchange-inline">concentrations (BAC) were </ins>2.11 and 2.49 g/L, respectively<ins class="diffchange diffchange-inline">)</ins>. <ins class="diffchange diffchange-inline">Forensic autopsy of both victims was performed four days after the time </ins>of <ins class="diffchange diffchange-inline">death following the Recommendation No</ins>.<ins class="diffchange diffchange-inline">R </ins>(<ins class="diffchange diffchange-inline">99</ins>)<ins class="diffchange diffchange-inline">3 of </ins>the <ins class="diffchange diffchange-inline">Council of Europe on medico</ins>-<ins class="diffchange diffchange-inline">legal autopsies. Elegans demonstrated </ins>the <ins class="diffchange diffchange-inline">ability to form all </ins>of the <ins class="diffchange diffchange-inline">in-vivo </ins>metabolites <ins class="diffchange diffchange-inline">and has </ins>the <ins class="diffchange diffchange-inline">potential to be used as a complementary model </ins>to <ins class="diffchange diffchange-inline">predict and characterize human metabolites</ins>, <ins class="diffchange diffchange-inline">as well as identifying possible drug toxicities for emerging SCBs. Thus</ins>, <ins class="diffchange diffchange-inline">identification of the relevant urinary markers was based primarily upon the prevalence of the </ins>in-vivo metabolites <ins class="diffchange diffchange-inline">instead </ins>of the <ins class="diffchange diffchange-inline">metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup</ins>, <ins class="diffchange diffchange-inline">physiological conditions (age</ins>, <ins class="diffchange diffchange-inline">gender adb butinaca and ethnicity)</ins>, <ins class="diffchange diffchange-inline">environmental influences (diet) </ins>and <ins class="diffchange diffchange-inline">pathological factors (liver diseases</ins>, <ins class="diffchange diffchange-inline">diabetes</ins>, and <ins class="diffchange diffchange-inline">obesity) would </ins>further <ins class="diffchange diffchange-inline">complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due </ins>to <ins class="diffchange diffchange-inline">differences in ionization capacity and matrix effects bias for each metabolite</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data concerning </ins>the <ins class="diffchange diffchange-inline">combined effects of SCRAs </ins>and other <ins class="diffchange diffchange-inline">substances are highly limited</ins>, <ins class="diffchange diffchange-inline">which renders forensic evaluation of possible overdose cases difficult </ins>. <ins class="diffchange diffchange-inline">The threshold SCRA concentration for fatal overdose can be estimated ng</ins>/<ins class="diffchange diffchange-inline">mL level </ins>(<ins class="diffchange diffchange-inline">0.37–4.1 ng</ins>/<ins class="diffchange diffchange-inline">mL according to the reported cases</ins>) in <ins class="diffchange diffchange-inline">cases in which 1</ins>.<ins class="diffchange diffchange-inline">5–2</ins>.<ins class="diffchange diffchange-inline">5 g</ins>/<ins class="diffchange diffchange-inline">L </ins>of <ins class="diffchange diffchange-inline">ethanol is present in </ins>the <ins class="diffchange diffchange-inline">blood</ins>. <ins class="diffchange diffchange-inline">The victims were brothers who were both found deceased after consuming </ins>4F-MDMB-BINACA and <ins class="diffchange diffchange-inline">ethanol</ins>. <ins class="diffchange diffchange-inline">These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public</ins>. <ins class="diffchange diffchange-inline">Monitoring metabolism </ins>of <ins class="diffchange diffchange-inline">synthetic cannabinoid </ins>4F-MDMB-BINACA <ins class="diffchange diffchange-inline">via high</ins>-<ins class="diffchange diffchange-inline">resolution mass spectrometry assessed </ins>in <ins class="diffchange diffchange-inline">cultured hepatoma cell line, fungus</ins>, <ins class="diffchange diffchange-inline">liver microsomes and confirmed using urine samples</ins>. <ins class="diffchange diffchange-inline">This article does not contain any studies with human participants or animals performed by any </ins>of <ins class="diffchange diffchange-inline">the author</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Figure 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">These synthetic cannabinoids act directly at cannabinoid CB1 </ins>and <ins class="diffchange diffchange-inline">CB2 receptors as does Δ9-tetrahydrocannabinol </ins>(<ins class="diffchange diffchange-inline">Δ9-THC</ins>) <ins class="diffchange diffchange-inline">found in marijuana</ins>, <ins class="diffchange diffchange-inline">but have different chemical structures unrelated </ins>to <ins class="diffchange diffchange-inline">Δ9-THC</ins>, <ins class="diffchange diffchange-inline">different metabolism</ins>, <ins class="diffchange diffchange-inline">and often greater toxicity </ins>(<ins class="diffchange diffchange-inline">Fantegrossi </ins>et al., 2014). <ins class="diffchange diffchange-inline">Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB</ins>-<ins class="diffchange diffchange-inline">FUBINACA, </ins>and <ins class="diffchange diffchange-inline">AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid</ins>-<ins class="diffchange diffchange-inline">like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">adb butinaca</ins>] <ins class="diffchange diffchange-inline">have been observed at doses that do not produce adverse effects</ins>, <ins class="diffchange diffchange-inline">although tremors were observed upon handling </ins>in <ins class="diffchange diffchange-inline">mice that received </ins>JWH-<ins class="diffchange diffchange-inline">210 (Gatch et al., 2016), and 5F</ins>-<ins class="diffchange diffchange-inline">AMB produced sustained vocalization </ins>and <ins class="diffchange diffchange-inline">convulsions in rats (Gatch et al., 2018). All </ins>of <ins class="diffchange diffchange-inline">the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects </ins>of <ins class="diffchange diffchange-inline">Δ9-THC. Subsequently</ins>, <ins class="diffchange diffchange-inline">a one</ins>-<ins class="diffchange diffchange-inline">way analysis </ins>of <ins class="diffchange diffchange-inline">variance </ins>was <ins class="diffchange diffchange-inline">conducted </ins>on <ins class="diffchange diffchange-inline">horizontal activity counts for </ins>the <ins class="diffchange diffchange-inline">30-min period </ins>of <ins class="diffchange diffchange-inline">maximal effect, and planned comparisons were conducted for each dose against </ins>the <ins class="diffchange diffchange-inline">vehicle control </ins>using <ins class="diffchange diffchange-inline">single degree</ins>-of<ins class="diffchange diffchange-inline">-freedom F tests</ins>. <ins class="diffchange diffchange-inline">A two-way analysis </ins>of <ins class="diffchange diffchange-inline">variance, with dose as </ins>a <ins class="diffchange diffchange-inline">between groups factor </ins>and <ins class="diffchange diffchange-inline">time as a within subject factor</ins>, <ins class="diffchange diffchange-inline">was conducted on horizontal activity counts/10 min interval</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gatch </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min</ins>, and <ins class="diffchange diffchange-inline">maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA </ins>in <ins class="diffchange diffchange-inline">3 </ins>of <ins class="diffchange diffchange-inline">8 mice </ins>(<ins class="diffchange diffchange-inline">data not shown</ins>)<ins class="diffchange diffchange-inline">. Substantial depressant effects were observed within the first 10 min, </ins>and <ins class="diffchange diffchange-inline">maximal depression was observed between 10–40 min and lasted up to 2</ins>.<ins class="diffchange diffchange-inline">5 to 3 h at </ins>the <ins class="diffchange diffchange-inline">highest dose tested </ins>(<ins class="diffchange diffchange-inline">0</ins>.<ins class="diffchange diffchange-inline">5 mg/kg</ins>). <ins class="diffchange diffchange-inline">Figure 1 shows average horizontal activity counts/10 min as a function </ins>of time (<ins class="diffchange diffchange-inline">0–4 h</ins>) and <ins class="diffchange diffchange-inline">dose </ins>of <ins class="diffchange diffchange-inline">Δ9-TH</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28421:rev-28426 --> </table>

CaroleHoller04 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28421&oldid=prev 2026-06-01T17:16:50Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:16 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The <del class="diffchange diffchange-inline">same procedure </del>was <del class="diffchange diffchange-inline">then applied to the mice once every day for 5 days</del>. <del class="diffchange diffchange-inline">It </del>was <del class="diffchange diffchange-inline">considered as coordination disturbance when mice fell from the test apparatus within </del>2 <del class="diffchange diffchange-inline">min</del>. <del class="diffchange diffchange-inline">Mice that remained their position on the running apparatus at 10 rpm for at least </del>2 <del class="diffchange diffchange-inline">min were selected for further evaluation</del>.<del class="diffchange diffchange-inline">&lt;br&gt;Table </del>of <del class="diffchange diffchange-inline">Conten</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Although there were reports on </del>the <del class="diffchange diffchange-inline">metabolism of </del>4F-MDMB-BINACA <del class="diffchange diffchange-inline">using in-vivo and various in-vitro models</del>, <del class="diffchange diffchange-inline">studies were either conducted using small </del>in<del class="diffchange diffchange-inline">-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons </del>. <del class="diffchange diffchange-inline">The hepatic cell line HepG2 is often used as an initial screen as it is known </del>to <del class="diffchange diffchange-inline">produce high reproducibility results with relatively stable enzyme concentration</del>, <del class="diffchange diffchange-inline">although they are limited by the low-level expression of several metabolizing enzymes</del>, <del class="diffchange diffchange-inline">including the cytochrome P450 </del>(<del class="diffchange diffchange-inline">CYP</del>) <del class="diffchange diffchange-inline">class of proteins [17, 18]</del>. <del class="diffchange diffchange-inline">In</del>-<del class="diffchange diffchange-inline">vitro </del>metabolism studies <del class="diffchange diffchange-inline">are generally used </del>to <del class="diffchange diffchange-inline">complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled </del>human <del class="diffchange diffchange-inline">liver microsomes (HLM) have been frequently used to elucidate metabolism </del>of <del class="diffchange diffchange-inline">SCBs [12</del>,<del class="diffchange diffchange-inline">13</del>,<del class="diffchange diffchange-inline">14</del>,<del class="diffchange diffchange-inline">15,16]</del>. <del class="diffchange diffchange-inline">Since most SCBs are found extensively </del>in <del class="diffchange diffchange-inline">metabolized forms in urine, the identification of </del>metabolites <del class="diffchange diffchange-inline">is </del>of <del class="diffchange diffchange-inline">vital importance for forensic </del>and <del class="diffchange diffchange-inline">clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs</del>. <del class="diffchange diffchange-inline">The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Synthetic cannabinoids </del>have <del class="diffchange diffchange-inline">consistently </del>been <del class="diffchange diffchange-inline">shown to produce discriminative stimulus effects similar to those https:</del>/<del class="diffchange diffchange-inline">/cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ of Δ9-THC </del>(<del class="diffchange diffchange-inline">Bannister and Connor</del>, <del class="diffchange diffchange-inline">2018</del>)<del class="diffchange diffchange-inline">, </del>and <del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">FUBINACA fully substituted for Δ9-THC </del>(<del class="diffchange diffchange-inline">Gamage et al.</del>, <del class="diffchange diffchange-inline">2018</del>)<del class="diffchange diffchange-inline">. The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability </del>(<del class="diffchange diffchange-inline">Fig. 1</del>). <del class="diffchange diffchange-inline">All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9</del>-<del class="diffchange diffchange-inline">THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present </del>in <del class="diffchange diffchange-inline">a total of ten people who had died from unexplained drug overdoses </del>in <del class="diffchange diffchange-inline">Japan between September 2014 and December 2014</del>. <del class="diffchange diffchange-inline">AMB-FUBINACA produced tremors and may be </del>of <del class="diffchange diffchange-inline">increased risk in human recreational users</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gatch </del>&lt;br&gt;<del class="diffchange diffchange-inline">Duration </del>of the <del class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0</del>.<del class="diffchange diffchange-inline">1 mg/kg to </del>2.<del class="diffchange diffchange-inline">5 h following 1 mg</del>/<del class="diffchange diffchange-inline">kg. Substantial depressant effects were observed within the first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA </del>in <del class="diffchange diffchange-inline">3 of 8 mice (</del>data <del class="diffchange diffchange-inline">not shown)</del>. <del class="diffchange diffchange-inline">Substantial depressant effects were observed within </del>the <del class="diffchange diffchange-inline">first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression </del>was <del class="diffchange diffchange-inline">observed </del>between <del class="diffchange diffchange-inline">10–40 min </del>and <del class="diffchange diffchange-inline">lasted up to </del>2.<del class="diffchange diffchange-inline">5 to 3 h at the highest dose tested (0.5 mg</del>/<del class="diffchange diffchange-inline">kg)</del>. <del class="diffchange diffchange-inline">Figure </del>1 <del class="diffchange diffchange-inline">shows average horizontal activity counts</del>/<del class="diffchange diffchange-inline">10 min as </del>a <del class="diffchange diffchange-inline">function </del>of <del class="diffchange diffchange-inline">time (0–4 h) and dose of Δ9-TH</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">These synthetic cannabinoids act directly at cannabinoid CB1 </del>and <del class="diffchange diffchange-inline">CB2 receptors as does Δ9-tetrahydrocannabinol </del>(<del class="diffchange diffchange-inline">Δ9-THC</del>) <del class="diffchange diffchange-inline">found in marijuana</del>, <del class="diffchange diffchange-inline">but have different chemical structures unrelated </del>to <del class="diffchange diffchange-inline">Δ9-THC</del>, <del class="diffchange diffchange-inline">different metabolism</del>, <del class="diffchange diffchange-inline">and often greater toxicity </del>(<del class="diffchange diffchange-inline">Fantegrossi </del>et al., 2014). <del class="diffchange diffchange-inline">Discriminative stimulus effects were tested in rats trained to discriminate Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol (3 mg</del>/<del class="diffchange diffchange-inline">kg, 30</del>-<del class="diffchange diffchange-inline">min pretreatment)</del>. <del class="diffchange diffchange-inline">5F-MDMB-PINACA (also known as 5F-</del>ADB, <del class="diffchange diffchange-inline">5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for </del>in <del class="diffchange diffchange-inline">vivo cannabinoid</del>-<del class="diffchange diffchange-inline">like effects to assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">A 30</del>-<del class="diffchange diffchange-inline">min period, beginning when maximal depression </del>of <del class="diffchange diffchange-inline">locomotor activity first appeared as </del>a <del class="diffchange diffchange-inline">function </del>of <del class="diffchange diffchange-inline">dose</del>, <del class="diffchange diffchange-inline">was used for analysis </del>of <del class="diffchange diffchange-inline">dose</del>-<del class="diffchange diffchange-inline">response data and calculation </del>of <del class="diffchange diffchange-inline">ED50 values. During </del>test <del class="diffchange diffchange-inline">sessions, both levers were active, such that ten consecutive responses </del>on <del class="diffchange diffchange-inline">either lever led to [https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/ https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/] reinforcement. The substitution tests occurred only if the rats had achieved 85% injection</del>-<del class="diffchange diffchange-inline">appropriate responding on the two prior training sessions</del>.&lt;br&gt;The <del class="diffchange diffchange-inline">locomotor activity assay was used to identify approximate </del>time <del class="diffchange diffchange-inline">courses </del>and <del class="diffchange diffchange-inline">dose ranges </del>of <del class="diffchange diffchange-inline">psychoactive effects, which is useful for identifying parameters for drug discrimination experiments </del>and <del class="diffchange diffchange-inline">are also predictive </del>of the <del class="diffchange diffchange-inline">time course of </del>the <del class="diffchange diffchange-inline">psychoactive effects in human users</del>. The <del class="diffchange diffchange-inline">purpose </del>of <del class="diffchange diffchange-inline">the present study was </del>to <del class="diffchange diffchange-inline">assess </del>the <del class="diffchange diffchange-inline">abuse liability </del>of <del class="diffchange diffchange-inline">5F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">PINACA, MDMB</del>-<del class="diffchange diffchange-inline">CHIMICA, MDMB</del>-<del class="diffchange diffchange-inline">FUBINACA, ADB</del>-<del class="diffchange diffchange-inline">FUBINACA, and AMB</del>-<del class="diffchange diffchange-inline">FUBINACA</del>. <del class="diffchange diffchange-inline">Since there is currently no robust measure of </del>the <del class="diffchange diffchange-inline">reinforcing/rewarding effects of cannabinoids</del>, <del class="diffchange diffchange-inline">drug discrimination is currently </del>the <del class="diffchange diffchange-inline">best model for assessing abuse liability </del>of <del class="diffchange diffchange-inline">cannabinoids. The findings produce an apparent paradox, since CPP </del>and <del class="diffchange diffchange-inline">self-administration predict with high reliability </del>the <del class="diffchange diffchange-inline">likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to the reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. </ins>The <ins class="diffchange diffchange-inline">concentration of 4F-MDMB-BINACA in the postmortem blood </ins>was <ins class="diffchange diffchange-inline">2.50 and 2</ins>.<ins class="diffchange diffchange-inline">34 ng/mL, and blood alcohol concentration </ins>was 2.<ins class="diffchange diffchange-inline">11 and </ins>2.<ins class="diffchange diffchange-inline">49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption </ins>of <ins class="diffchange diffchange-inline">4F-MDMB-BINACA and ethanol.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 2. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than </ins>the <ins class="diffchange diffchange-inline">parent drug, </ins>4F-MDMB-BINACA, <ins class="diffchange diffchange-inline">suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown </ins>in <ins class="diffchange diffchange-inline">Fig</ins>. <ins class="diffchange diffchange-inline">Metabolites were identified according </ins>to <ins class="diffchange diffchange-inline">their precursor ions</ins>, <ins class="diffchange diffchange-inline">product ions</ins>, <ins class="diffchange diffchange-inline">and fragmentation patterns </ins>(<ins class="diffchange diffchange-inline">Fig. 1</ins>). <ins class="diffchange diffchange-inline">Traditional in</ins>-<ins class="diffchange diffchange-inline">vivo </ins>metabolism studies to <ins class="diffchange diffchange-inline">generate </ins>human <ins class="diffchange diffchange-inline">metabolites of drugs relied heavily on the use </ins>of <ins class="diffchange diffchange-inline">whole animal model systems</ins>, <ins class="diffchange diffchange-inline">which are expensive</ins>, <ins class="diffchange diffchange-inline">limited by drug administration amount</ins>, <ins class="diffchange diffchange-inline">influenced by species variation and faced by many ethical issues</ins>. <ins class="diffchange diffchange-inline">Eight </ins>in<ins class="diffchange diffchange-inline">-vivo </ins>metabolites <ins class="diffchange diffchange-inline">tentatively identified were mainly products </ins>of <ins class="diffchange diffchange-inline">ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation </ins>and <ins class="diffchange diffchange-inline">oxidative defluorination with further oxidation to butanoic acid</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">This outcome was anticipated since CES-mediated hydrolysis is commonly 4F ADB reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites </ins>have been <ins class="diffchange diffchange-inline">reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m</ins>/<ins class="diffchange diffchange-inline">z 350)</ins>. <ins class="diffchange diffchange-inline">Both ester hydrolysis followed by oxidative defluorination to butanoic acid </ins>(<ins class="diffchange diffchange-inline">B4</ins>, <ins class="diffchange diffchange-inline">m/z 362</ins>) and <ins class="diffchange diffchange-inline">monohydroxylation at tert</ins>-<ins class="diffchange diffchange-inline">leucine moiety </ins>(<ins class="diffchange diffchange-inline">B8</ins>, <ins class="diffchange diffchange-inline">m/z 366</ins>) <ins class="diffchange diffchange-inline">metabolites were found in 16/20 urine samples </ins>(<ins class="diffchange diffchange-inline">Table 2</ins>). <ins class="diffchange diffchange-inline">A In</ins>-<ins class="diffchange diffchange-inline">vitro metabolites observed </ins>in <ins class="diffchange diffchange-inline">common among respective seven most abundant metabolites </ins>in <ins class="diffchange diffchange-inline">b C</ins>. <ins class="diffchange diffchange-inline">The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity </ins>of <ins class="diffchange diffchange-inline">the sulfation metabolite</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Fungus C. elegans </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Concentrations </ins>of <ins class="diffchange diffchange-inline">4F-MDMB-BINACA in </ins>the <ins class="diffchange diffchange-inline">postmortem blood samples were 2</ins>.<ins class="diffchange diffchange-inline">50 and </ins>2.<ins class="diffchange diffchange-inline">34 ng</ins>/<ins class="diffchange diffchange-inline">mL</ins>, <ins class="diffchange diffchange-inline">which are </ins>in <ins class="diffchange diffchange-inline">line with published </ins>data. <ins class="diffchange diffchange-inline">Although </ins>the <ins class="diffchange diffchange-inline">lethal dose of 4F-MDMB-BINACA is unknown</ins>, <ins class="diffchange diffchange-inline">its concentration in postmortem blood samples </ins>was <ins class="diffchange diffchange-inline">found to range </ins>between <ins class="diffchange diffchange-inline">0.10 </ins>and 2.<ins class="diffchange diffchange-inline">90 ng</ins>/<ins class="diffchange diffchange-inline">mL </ins>. <ins class="diffchange diffchange-inline">In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than </ins>1 <ins class="diffchange diffchange-inline">ng</ins>/<ins class="diffchange diffchange-inline">mL . Concentrations of SCRAs in postmortem cases cover </ins>a <ins class="diffchange diffchange-inline">wide range ; however, some reports </ins>of <ins class="diffchange diffchange-inline">survival have also been published—even at relatively high blood SCRA concentrations [19, 20</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) </ins>and <ins class="diffchange diffchange-inline">positive </ins>(<ins class="diffchange diffchange-inline">methamphetamine</ins>) <ins class="diffchange diffchange-inline">controls. After the last administration</ins>, <ins class="diffchange diffchange-inline">the first trial was performed. Morris water maze test was performed </ins>to <ins class="diffchange diffchange-inline">evaluate the changes of learning and memory function through administration of the test substances. Generally</ins>, <ins class="diffchange diffchange-inline">neurotoxicity of a substance is evaluated by animal behavioral aspects</ins>, <ins class="diffchange diffchange-inline">i.e. functional observation battery (FOB) tests </ins>(<ins class="diffchange diffchange-inline">O’Callaghan </ins>et al., 2014). <ins class="diffchange diffchange-inline">Our results suggest that JWH-081 and JWH</ins>-<ins class="diffchange diffchange-inline">210 may [https:/</ins>/<ins class="diffchange diffchange-inline">cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb</ins>.<ins class="diffchange diffchange-inline">com/ 4F </ins>ADB<ins class="diffchange diffchange-inline">] be neurotoxic substances through changing neuronal cell damages</ins>, <ins class="diffchange diffchange-inline">especially </ins>in <ins class="diffchange diffchange-inline">the core shell part of nucleus accumbens.&lt;br&gt;About Powder JWH</ins>-<ins class="diffchange diffchange-inline">2</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">High resolution mass spectrometry such as LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS allows the detection and identification </ins>of a <ins class="diffchange diffchange-inline">broad spectrum </ins>of <ins class="diffchange diffchange-inline">recreational drugs</ins>, <ins class="diffchange diffchange-inline">including new psychoactive substances. A point-</ins>of-<ins class="diffchange diffchange-inline">care drugs </ins>of <ins class="diffchange diffchange-inline">abuse (DOA) </ins>test <ins class="diffchange diffchange-inline">was initially performed </ins>on <ins class="diffchange diffchange-inline">the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e</ins>-<ins class="diffchange diffchange-inline">cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms</ins>. <ins class="diffchange diffchange-inline">He usually smokes a pack of cigarettes a day and sometimes smokes e</ins>-<ins class="diffchange diffchange-inline">cigarettes</ins>. <ins class="diffchange diffchange-inline">Combined with non</ins>-<ins class="diffchange diffchange-inline">specific, transient symptoms, clinical recognition of SCRA intoxication is challenging </ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Data availability </ins>&lt;br&gt;The <ins class="diffchange diffchange-inline">intensity is plotted against the retention </ins>time <ins class="diffchange diffchange-inline">for both chromatograms, demonstrating the 4F ADB presence </ins>and <ins class="diffchange diffchange-inline">elution profiles </ins>of <ins class="diffchange diffchange-inline">nicotine </ins>and <ins class="diffchange diffchange-inline">ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms </ins>of <ins class="diffchange diffchange-inline">Nicotine (Top) and ADB-BUTINACA (Bottom) in </ins>the <ins class="diffchange diffchange-inline">Vape Liquid used by </ins>the <ins class="diffchange diffchange-inline">patient</ins>. The <ins class="diffchange diffchange-inline">LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-</ins>of<ins class="diffchange diffchange-inline">-care DOA test is generally not able </ins>to <ins class="diffchange diffchange-inline">detect synthetic recreational drug substances, </ins>the <ins class="diffchange diffchange-inline">liquid </ins>of <ins class="diffchange diffchange-inline">the e</ins>-<ins class="diffchange diffchange-inline">cigarette was thereafter screened using liquid chromatography</ins>-<ins class="diffchange diffchange-inline">quadrupole time</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">flight mass spectrometry (LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS) on the Waters™ Xevo G3 QTOF MS system</ins>. <ins class="diffchange diffchange-inline">After eating a light meal and drinking caffeinated sports drinks at </ins>the <ins class="diffchange diffchange-inline">ER</ins>, the <ins class="diffchange diffchange-inline">nausea complaints </ins>of <ins class="diffchange diffchange-inline">the patient were reduced </ins>and the <ins class="diffchange diffchange-inline">patient was discharged hom</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28410:rev-28421 --> </table>

AlizaMoberg10 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28410&oldid=prev 2026-06-01T17:13:41Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:13 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Due </del>to the <del class="diffchange diffchange-inline">unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging</del>. <del class="diffchange diffchange-inline">According to </del>the <del class="diffchange diffchange-inline">reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was </del>2.<del class="diffchange diffchange-inline">50 and 2.34 ng/mL, and blood alcohol concentration was 2.11 and 2.49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol.&lt;br&gt;Fig. 2. &lt;br&gt;The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to </del>their <del class="diffchange diffchange-inline">precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily </del>on the <del class="diffchange diffchange-inline">use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified </del>were <del class="diffchange diffchange-inline">mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with </del>further <del class="diffchange diffchange-inline">oxidation to butanoic acid.&lt;br&gt;Fig. 1</del>. &lt;br&gt;<del class="diffchange diffchange-inline">This outcome was anticipated since CES-mediated hydrolysis is commonly https://cannabinoidsrc4f-adb.com/ reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (</del>Table <del class="diffchange diffchange-inline">2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss </del>of <del class="diffchange diffchange-inline">sulfate, confirmed the identity of the sulfation metabolite.&lt;br&gt;Fungus C. elegans &lt;br&gt;Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law&lt;br&gt;&lt;br&gt;The <del class="diffchange diffchange-inline">test apparatus for </del>the locomotor activity <del class="diffchange diffchange-inline">test was designed </del>to <del class="diffchange diffchange-inline">measure locomotor activity automatically using UV system (AM 1051</del>, <del class="diffchange diffchange-inline">Benwick Electronics, Benwick, UK) when experimental animals moved </del>in <del class="diffchange diffchange-inline">the chambe</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;All </del>of the <del class="diffchange diffchange-inline">compounds tested </del>in the <del class="diffchange diffchange-inline">present study depressed locomotor activity as is typical for other synthetic cannabinoids </del>(<del class="diffchange diffchange-inline">see review by Wiley et al</del>.<del class="diffchange diffchange-inline">, 2017</del>). <del class="diffchange diffchange-inline">Average </del>horizontal activity counts/10 min as a function of time (<del class="diffchange diffchange-inline">10 min bins</del>) and dose. <del class="diffchange diffchange-inline">Depressant </del>effects <del class="diffchange diffchange-inline">of 1.33 </del>mg/kg were <del class="diffchange diffchange-inline">observed within 10 </del>min <del class="diffchange diffchange-inline">following administration </del>and <del class="diffchange diffchange-inline">peak depressant effects </del>were [https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] <del class="diffchange diffchange-inline">observed between 0–30 min</del>. <del class="diffchange diffchange-inline">Duration of </del>the <del class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2</del>.<del class="diffchange diffchange-inline">5 h following 1 mg/k</del>&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;Moreover</del>, <del class="diffchange diffchange-inline">a study conducted in </del>the <del class="diffchange diffchange-inline">United Kingdom investigated components </del>of <del class="diffchange diffchange-inline">e-liquids </del>in <del class="diffchange diffchange-inline">112 samples originating from prisoners, teenagers and test purchases </del>of <del class="diffchange diffchange-inline">commercially available e-cigarettes taken between 2014 and 2021 . This is </del>the <del class="diffchange diffchange-inline">first case report that describes </del>the <del class="diffchange diffchange-inline">toxicological symptoms </del>of <del class="diffchange diffchange-inline">vaping ADB</del>-<del class="diffchange diffchange-inline">BUTINACA. Results of the DOA test (including testing for amphetamines</del>, <del class="diffchange diffchange-inline">methamphetamines</del>, <del class="diffchange diffchange-inline">barbiturates</del>, <del class="diffchange diffchange-inline">benzodiazepines, cocaine, methadone, opioids, cannabis</del>, <del class="diffchange diffchange-inline">tricyclic antidepressants) were available within 30 minutes </del>and <del class="diffchange diffchange-inline">were all negative</del>. <del class="diffchange diffchange-inline">We report a case </del>of <del class="diffchange diffchange-inline">an involuntary intoxication </del>of the <del class="diffchange diffchange-inline">SCRA ADB</del>-<del class="diffchange diffchange-inline">BUTINACA after vaping. There </del>are <del class="diffchange diffchange-inline">several pitfalls </del>in <del class="diffchange diffchange-inline">the detection of SCRA in samples taken from the patient.&lt;br&gt;Data availabili</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">The same procedure was then applied </ins>to the <ins class="diffchange diffchange-inline">mice once every day for 5 days</ins>. <ins class="diffchange diffchange-inline">It was considered as coordination disturbance when mice fell from </ins>the <ins class="diffchange diffchange-inline">test apparatus within </ins>2 <ins class="diffchange diffchange-inline">min</ins>. <ins class="diffchange diffchange-inline">Mice that remained </ins>their <ins class="diffchange diffchange-inline">position </ins>on the <ins class="diffchange diffchange-inline">running apparatus at 10 rpm for at least 2 min </ins>were <ins class="diffchange diffchange-inline">selected for </ins>further <ins class="diffchange diffchange-inline">evaluation</ins>.&lt;br&gt;Table of <ins class="diffchange diffchange-inline">Conten</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">&lt;br&gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those https://cannabinoidsrc4f-adb.com/ of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). </ins>The <ins class="diffchange diffchange-inline">chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on </ins>the <ins class="diffchange diffchange-inline">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased </ins>locomotor activity <ins class="diffchange diffchange-inline">and produced discriminative stimulus effects similar </ins>to <ins class="diffchange diffchange-inline">those of Δ9-THC</ins>, <ins class="diffchange diffchange-inline">which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk </ins>in <ins class="diffchange diffchange-inline">human recreational users.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gatch </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Duration </ins>of the <ins class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA </ins>in <ins class="diffchange diffchange-inline">3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at </ins>the <ins class="diffchange diffchange-inline">highest dose tested </ins>(<ins class="diffchange diffchange-inline">0</ins>.<ins class="diffchange diffchange-inline">5 mg/kg</ins>). <ins class="diffchange diffchange-inline">Figure 1 shows average </ins>horizontal activity counts/10 min as a function of time (<ins class="diffchange diffchange-inline">0–4 h</ins>) and dose <ins class="diffchange diffchange-inline">of Δ9-TH&lt;br&gt;&lt;br&gt;&lt;br&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014)</ins>. <ins class="diffchange diffchange-inline">Discriminative stimulus </ins>effects <ins class="diffchange diffchange-inline">were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 </ins>mg/kg<ins class="diffchange diffchange-inline">, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) </ins>were <ins class="diffchange diffchange-inline">tested for in vivo cannabinoid-like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;A 30-</ins>min <ins class="diffchange diffchange-inline">period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data </ins>and <ins class="diffchange diffchange-inline">calculation of ED50 values. During test sessions, both levers </ins>were <ins class="diffchange diffchange-inline">active, such that ten consecutive responses on either lever led to </ins>[https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] <ins class="diffchange diffchange-inline">reinforcement</ins>. <ins class="diffchange diffchange-inline">The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on </ins>the <ins class="diffchange diffchange-inline">two prior training sessions</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects</ins>, <ins class="diffchange diffchange-inline">which is useful for identifying parameters for drug discrimination experiments and are also predictive of </ins>the <ins class="diffchange diffchange-inline">time course </ins>of <ins class="diffchange diffchange-inline">the psychoactive effects </ins>in <ins class="diffchange diffchange-inline">human users. The purpose </ins>of the <ins class="diffchange diffchange-inline">present study was to assess </ins>the <ins class="diffchange diffchange-inline">abuse liability </ins>of <ins class="diffchange diffchange-inline">5F-MDMB</ins>-<ins class="diffchange diffchange-inline">PINACA</ins>, <ins class="diffchange diffchange-inline">MDMB-CHIMICA</ins>, <ins class="diffchange diffchange-inline">MDMB-FUBINACA</ins>, <ins class="diffchange diffchange-inline">ADB-FUBINACA</ins>, and <ins class="diffchange diffchange-inline">AMB-FUBINACA</ins>. <ins class="diffchange diffchange-inline">Since there is currently no robust measure </ins>of <ins class="diffchange diffchange-inline">the reinforcing/rewarding effects </ins>of <ins class="diffchange diffchange-inline">cannabinoids, drug discrimination is currently </ins>the <ins class="diffchange diffchange-inline">best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self</ins>-<ins class="diffchange diffchange-inline">administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids </ins>are <ins class="diffchange diffchange-inline">well-known to produce active drug-seeking </ins>in <ins class="diffchange diffchange-inline">human</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28396:rev-28410 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28396&oldid=prev 2026-06-01T17:09:21Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:09 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">These synthetic cannabinoids act [https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ JWH-210 powder] directly at cannabinoid CB1 </del>and <del class="diffchange diffchange-inline">CB2 receptors as does Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol (Δ9</del>-<del class="diffchange diffchange-inline">THC) found </del>in <del class="diffchange diffchange-inline">marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism</del>, and <del class="diffchange diffchange-inline">often greater toxicity (Fantegrossi et al</del>.<del class="diffchange diffchange-inline">, 2014)</del>. <del class="diffchange diffchange-inline">Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg</del>/<del class="diffchange diffchange-inline">kg</del>, <del class="diffchange diffchange-inline">30-min pretreatment)</del>. <del class="diffchange diffchange-inline">5F</del>-MDMB-<del class="diffchange diffchange-inline">PINACA </del>(<del class="diffchange diffchange-inline">also known as 5F-ADB</del>, <del class="diffchange diffchange-inline">5F-ADB-PINACA</del>), MDMB-<del class="diffchange diffchange-inline">CHIMICA</del>, <del class="diffchange diffchange-inline">MDMB-FUBINACA</del>, <del class="diffchange diffchange-inline">ADB-FUBINACA</del>, and <del class="diffchange diffchange-inline">AMB-FUBINACA </del>(<del class="diffchange diffchange-inline">also known as FUB</del>-<del class="diffchange diffchange-inline">AMB</del>, <del class="diffchange diffchange-inline">MMB</del>-<del class="diffchange diffchange-inline">FUBINACA) </del>were <del class="diffchange diffchange-inline">tested for in vivo cannabinoid</del>-<del class="diffchange diffchange-inline">like effects </del>to <del class="diffchange diffchange-inline">assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Metabolic Profile of Synthetic Cannabinoids 5F</del>-<del class="diffchange diffchange-inline">PB</del>-<del class="diffchange diffchange-inline">22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans &lt;br&gt;This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation </del>. <del class="diffchange diffchange-inline">HepG2 model detected </del>the major ester hydrolysis metabolite <del class="diffchange diffchange-inline">of 4F</del>-<del class="diffchange diffchange-inline">MDMB-BINACA in abundance but the rest of the </del>metabolites were found in <del class="diffchange diffchange-inline">a small amount</del>. <del class="diffchange diffchange-inline">Elegans and HLM models detected all of the in</del>-<del class="diffchange diffchange-inline">vivo </del>metabolites <del class="diffchange diffchange-inline">(100%), whilst HepG2 cells detected 7 out of the 8 </del>in<del class="diffchange diffchange-inline">-vivo </del>metabolites <del class="diffchange diffchange-inline">(87</del>.<del class="diffchange diffchange-inline">5%). Hence</del>, <del class="diffchange diffchange-inline">structural elucidation could not be </del>confirmed <del class="diffchange diffchange-inline">unless a reference standard is made availabl</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma</del>-<del class="diffchange diffchange-inline">hydroxybutyrate (GHB) </del>and <del class="diffchange diffchange-inline">ketamine </del>are <del class="diffchange diffchange-inline">likely to become volatile under </del>the <del class="diffchange diffchange-inline">temperature </del>of <del class="diffchange diffchange-inline">current e</del>-<del class="diffchange diffchange-inline">cigarettes</del>, <del class="diffchange diffchange-inline">while crack cocaine is hard </del>to <del class="diffchange diffchange-inline">vaporis&lt;br&gt;&lt;br&gt;Subsequently, a one</del>-<del class="diffchange diffchange-inline">way analysis of variance was conducted on horizontal activity counts for </del>the <del class="diffchange diffchange-inline">30-min period of maximal effect</del>, <del class="diffchange diffchange-inline">and planned comparisons were conducted for each dose against </del>the <del class="diffchange diffchange-inline">vehicle control using single degree-of-freedom F test&lt;br&gt;&lt;br&gt;The chemical structures of </del>the <del class="diffchange diffchange-inline">recent synthetic cannabinoids are unlike that </del>of <del class="diffchange diffchange-inline">Δ9-THC</del>, <del class="diffchange diffchange-inline">but are largely based on the structure </del>of <del class="diffchange diffchange-inline">older synthetic cannabinoids that are known to </del>have <del class="diffchange diffchange-inline">substantial abuse liability (Fig. 1</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Locomotor activity </del>in <del class="diffchange diffchange-inline">mice was tested to screen for locomotor depressant effects </del>and to <del class="diffchange diffchange-inline">identify behaviorally-active dose ranges </del>and <del class="diffchange diffchange-inline">times of peak effect</del>. <del class="diffchange diffchange-inline">Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids </del>known to <del class="diffchange diffchange-inline">have substantial abuse liability and act at </del>the <del class="diffchange diffchange-inline">CB1 receptor. Tremors were not observed following AMB</del>-<del class="diffchange diffchange-inline">FUBINACA during </del>the <del class="diffchange diffchange-inline">drug discrimination study</del>, <del class="diffchange diffchange-inline">but the maximum dose tested was only 0</del>.<del class="diffchange diffchange-inline">1 mg/kg</del>, which <del class="diffchange diffchange-inline">is 10-fold lower than the dose that produced tremors in the mice</del>. <del class="diffchange diffchange-inline">AMB-FUBINACA has been implicated </del>in <del class="diffchange diffchange-inline">severe adverse effects </del>in <del class="diffchange diffchange-inline">recreational users (Adams et al., 2017; Hamilton et al.</del>, <del class="diffchange diffchange-inline">2017), which suggests that </del>the <del class="diffchange diffchange-inline">range between behaviorally active and toxic doses </del>of <del class="diffchange diffchange-inline">AMB-FUBINACA </del>is <del class="diffchange diffchange-inline">narrow. Following that line </del>of <del class="diffchange diffchange-inline">reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves </del>and <del class="diffchange diffchange-inline">one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch </del>and <del class="diffchange diffchange-inline">Forster, 2018)</del>. <del class="diffchange diffchange-inline">All </del>of <del class="diffchange diffchange-inline">the </del>compounds <del class="diffchange diffchange-inline">identified as available on </del>the <del class="diffchange diffchange-inline">recreational </del>market <del class="diffchange diffchange-inline">and submitted </del>to <del class="diffchange diffchange-inline">our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during </del>the test <del class="diffchange diffchange-inline">session were excluded from </del>the <del class="diffchange diffchange-inline">analysis of the discriminative stimulus effects of that dose of test compoun</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA </del>in the present study<del class="diffchange diffchange-inline">. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the </del>locomotor activity <del class="diffchange diffchange-inline">assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg </del>(<del class="diffchange diffchange-inline">Gatch </del>et al., <del class="diffchange diffchange-inline">2014</del>)<del class="diffchange diffchange-inline">, whereas the potency of a recent set was 0</del>.<del class="diffchange diffchange-inline">09±0.03 mg</del>/<del class="diffchange diffchange-inline">kg </del>(<del class="diffchange diffchange-inline">Gatch et al., 2018</del>)<del class="diffchange diffchange-inline">, </del>and <del class="diffchange diffchange-inline">the potency </del>of <del class="diffchange diffchange-inline">the current set is 0</del>.<del class="diffchange diffchange-inline">05±0.01 </del>mg/kg<del class="diffchange diffchange-inline">. Short-onset, short-acting compounds have a greater abuse liability, </del>and <del class="diffchange diffchange-inline">long</del>-<del class="diffchange diffchange-inline">acting compounds pose problems of long</del>-<del class="diffchange diffchange-inline">acting adverse effects and interactions with other drugs</del>. <del class="diffchange diffchange-inline">The duration of action </del>of the <del class="diffchange diffchange-inline">synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than </del>1 <del class="diffchange diffchange-inline">h, others producing a duration of action between 1–2 h, and others lasting more than </del>2 h<del class="diffchange diffchange-inline">. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Thirty minutes prior to </del>the <del class="diffchange diffchange-inline">training sessions</del>, <del class="diffchange diffchange-inline">rats received an injection </del>of <del class="diffchange diffchange-inline">either vehicle or Δ9</del>-<del class="diffchange diffchange-inline">THC </del>and <del class="diffchange diffchange-inline">were subsequently placed in </del>the <del class="diffchange diffchange-inline">behavior</del>-testing <del class="diffchange diffchange-inline">chambers</del>, <del class="diffchange diffchange-inline">where food (45-mg food pellets; Bio-Serve</del>, <del class="diffchange diffchange-inline">Frenchtown</del>, <del class="diffchange diffchange-inline">NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate leve&lt;br&gt;&lt;br&gt;&lt;br&gt;After the incubation</del>, <del class="diffchange diffchange-inline">mixture was centrifuged (18</del>,<del class="diffchange diffchange-inline">000 x g</del>, <del class="diffchange diffchange-inline">20 °C</del>) <del class="diffchange diffchange-inline">for 5 min </del>and <del class="diffchange diffchange-inline">0</del>.<del class="diffchange diffchange-inline">5 μL </del>of the <del class="diffchange diffchange-inline">supernatant was directly injected to the chromatographic system</del>. <del class="diffchange diffchange-inline">In </del>the <del class="diffchange diffchange-inline">next step, ammonium formate as salting agent was added to the mixture and incubated </del>in <del class="diffchange diffchange-inline">a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, </del>the <del class="diffchange diffchange-inline">mixture was allowed to stand JWH-210 powder at room temperature for 5 min</del>. <del class="diffchange diffchange-inline">MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging</ins>. <ins class="diffchange diffchange-inline">According to the reported cases </ins>and <ins class="diffchange diffchange-inline">reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA </ins>in <ins class="diffchange diffchange-inline">the postmortem blood was 2.50 and 2.34 ng/mL</ins>, and <ins class="diffchange diffchange-inline">blood alcohol concentration was 2</ins>.<ins class="diffchange diffchange-inline">11 and 2</ins>.<ins class="diffchange diffchange-inline">49 g</ins>/<ins class="diffchange diffchange-inline">L</ins>, <ins class="diffchange diffchange-inline">respectively</ins>. <ins class="diffchange diffchange-inline">Two fatal cases are reported caused by simultaneous consumption of 4F</ins>-MDMB-<ins class="diffchange diffchange-inline">BINACA and ethanol.&lt;br&gt;Fig. 2. &lt;br&gt;The precursor ion m/z 396 </ins>(<ins class="diffchange diffchange-inline">B10</ins>, <ins class="diffchange diffchange-inline">B12/B15</ins>) <ins class="diffchange diffchange-inline">was 32 Da higher than the parent drug</ins>, <ins class="diffchange diffchange-inline">4F-</ins>MDMB-<ins class="diffchange diffchange-inline">BINACA</ins>, <ins class="diffchange diffchange-inline">suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions</ins>, <ins class="diffchange diffchange-inline">product ions</ins>, and <ins class="diffchange diffchange-inline">fragmentation patterns </ins>(<ins class="diffchange diffchange-inline">Fig. 1). Traditional in</ins>-<ins class="diffchange diffchange-inline">vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems</ins>, <ins class="diffchange diffchange-inline">which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in</ins>-<ins class="diffchange diffchange-inline">vivo metabolites tentatively identified </ins>were <ins class="diffchange diffchange-inline">mainly products of ester hydrolysis with or without additional dehydrogenation, N</ins>-<ins class="diffchange diffchange-inline">dealkylation, monohydroxylation and oxidative defluorination with further oxidation </ins>to <ins class="diffchange diffchange-inline">butanoic acid.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">This outcome was anticipated since CES</ins>-<ins class="diffchange diffchange-inline">mediated hydrolysis is commonly https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb</ins>.<ins class="diffchange diffchange-inline">com/ reported as </ins>the major <ins class="diffchange diffchange-inline">metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an </ins>ester hydrolysis metabolite <ins class="diffchange diffchange-inline">(m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert</ins>-<ins class="diffchange diffchange-inline">leucine moiety (B8, m/z 366) </ins>metabolites were found in <ins class="diffchange diffchange-inline">16/20 urine samples (Table 2)</ins>. <ins class="diffchange diffchange-inline">A In</ins>-<ins class="diffchange diffchange-inline">vitro </ins>metabolites <ins class="diffchange diffchange-inline">observed </ins>in <ins class="diffchange diffchange-inline">common among respective seven most abundant </ins>metabolites <ins class="diffchange diffchange-inline">in b C</ins>. <ins class="diffchange diffchange-inline">The product ion detected at m/z 235, indicating loss of sulfate</ins>, confirmed <ins class="diffchange diffchange-inline">the identity of the sulfation metabolite.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Fungus C. elegans </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Concentrations of 4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA in the postmortem blood samples were 2.50 </ins>and <ins class="diffchange diffchange-inline">2.34 ng/mL, which </ins>are <ins class="diffchange diffchange-inline">in line with published data. Although </ins>the <ins class="diffchange diffchange-inline">lethal dose </ins>of <ins class="diffchange diffchange-inline">4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA is unknown</ins>, <ins class="diffchange diffchange-inline">its concentration in postmortem blood samples was found </ins>to <ins class="diffchange diffchange-inline">range between 0.10 and 2.90 ng/mL . In SCRA</ins>-<ins class="diffchange diffchange-inline">related cases in which </ins>the <ins class="diffchange diffchange-inline">deceased suffered from heart disease</ins>, the <ins class="diffchange diffchange-inline">SCRA concentration in </ins>the <ins class="diffchange diffchange-inline">postmortem blood was less than 1 ng/mL . Concentrations </ins>of <ins class="diffchange diffchange-inline">SCRAs in postmortem cases cover a wide range ; however</ins>, <ins class="diffchange diffchange-inline">some reports </ins>of <ins class="diffchange diffchange-inline">survival </ins>have <ins class="diffchange diffchange-inline">also been published—even at relatively high blood SCRA concentrations [19, 20</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Although there were reports on the metabolism of 4F-MDMB-BINACA using </ins>in<ins class="diffchange diffchange-inline">-vivo </ins>and <ins class="diffchange diffchange-inline">various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 </ins>to <ins class="diffchange diffchange-inline">4 samples [5, 29] or in closed environments such as forensic psychiatric wards </ins>and <ins class="diffchange diffchange-inline">prisons </ins>. <ins class="diffchange diffchange-inline">The hepatic cell line HepG2 is often used as an initial screen as it is </ins>known to <ins class="diffchange diffchange-inline">produce high reproducibility results with relatively stable enzyme concentration, although they are limited by </ins>the <ins class="diffchange diffchange-inline">low</ins>-<ins class="diffchange diffchange-inline">level expression of several metabolizing enzymes, including </ins>the <ins class="diffchange diffchange-inline">cytochrome P450 (CYP) class of proteins [17</ins>, <ins class="diffchange diffchange-inline">18]</ins>. <ins class="diffchange diffchange-inline">In-vitro metabolism studies are generally used to complement these data using perfused organs</ins>, <ins class="diffchange diffchange-inline">tissue or cell cultures and microsomal preparations amongst </ins>which <ins class="diffchange diffchange-inline">pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]</ins>. <ins class="diffchange diffchange-inline">Since most SCBs are found extensively </ins>in <ins class="diffchange diffchange-inline">metabolized forms </ins>in <ins class="diffchange diffchange-inline">urine</ins>, the <ins class="diffchange diffchange-inline">identification </ins>of <ins class="diffchange diffchange-inline">metabolites </ins>is of <ins class="diffchange diffchange-inline">vital importance for forensic </ins>and <ins class="diffchange diffchange-inline">clinical toxicologists. Identifying SCB intake </ins>and <ins class="diffchange diffchange-inline">its correlating specific adverse effects require rapid elucidation of these SCBs</ins>. <ins class="diffchange diffchange-inline">The proliferation </ins>of <ins class="diffchange diffchange-inline">SCBs has become a global challenge as new </ins>compounds <ins class="diffchange diffchange-inline">are rapidly introduced into </ins>the <ins class="diffchange diffchange-inline">illegal drug </ins>market to <ins class="diffchange diffchange-inline">evade existing drug law</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">The test apparatus for </ins>the <ins class="diffchange diffchange-inline">locomotor activity </ins>test <ins class="diffchange diffchange-inline">was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in </ins>the <ins class="diffchange diffchange-inline">chambe</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">All of the compounds tested </ins>in the present study <ins class="diffchange diffchange-inline">depressed </ins>locomotor activity <ins class="diffchange diffchange-inline">as is typical for other synthetic cannabinoids </ins>(<ins class="diffchange diffchange-inline">see review by Wiley </ins>et al., <ins class="diffchange diffchange-inline">2017</ins>). <ins class="diffchange diffchange-inline">Average horizontal activity counts</ins>/<ins class="diffchange diffchange-inline">10 min as a function of time </ins>(<ins class="diffchange diffchange-inline">10 min bins</ins>) and <ins class="diffchange diffchange-inline">dose. Depressant effects </ins>of <ins class="diffchange diffchange-inline">1</ins>.<ins class="diffchange diffchange-inline">33 </ins>mg/kg <ins class="diffchange diffchange-inline">were observed within 10 min following administration </ins>and <ins class="diffchange diffchange-inline">peak depressant effects were [https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com/ https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com/] observed between 0–30 min</ins>. <ins class="diffchange diffchange-inline">Duration </ins>of the <ins class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0.</ins>1 <ins class="diffchange diffchange-inline">mg/kg to </ins>2<ins class="diffchange diffchange-inline">.5 </ins>h <ins class="diffchange diffchange-inline">following 1 mg/k&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Moreover, a study conducted in </ins>the <ins class="diffchange diffchange-inline">United Kingdom investigated components of e-liquids in 112 samples originating from prisoners</ins>, <ins class="diffchange diffchange-inline">teenagers and test purchases </ins>of <ins class="diffchange diffchange-inline">commercially available e</ins>-<ins class="diffchange diffchange-inline">cigarettes taken between 2014 </ins>and <ins class="diffchange diffchange-inline">2021 . This is the first case report that describes </ins>the <ins class="diffchange diffchange-inline">toxicological symptoms of vaping ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA. Results of the DOA test (including </ins>testing <ins class="diffchange diffchange-inline">for amphetamines</ins>, <ins class="diffchange diffchange-inline">methamphetamines, barbiturates, benzodiazepines</ins>, <ins class="diffchange diffchange-inline">cocaine</ins>, <ins class="diffchange diffchange-inline">methadone</ins>, <ins class="diffchange diffchange-inline">opioids</ins>, <ins class="diffchange diffchange-inline">cannabis</ins>, <ins class="diffchange diffchange-inline">tricyclic antidepressants</ins>) <ins class="diffchange diffchange-inline">were available within 30 minutes </ins>and <ins class="diffchange diffchange-inline">were all negative</ins>. <ins class="diffchange diffchange-inline">We report a case of an involuntary intoxication </ins>of the <ins class="diffchange diffchange-inline">SCRA ADB-BUTINACA after vaping</ins>. <ins class="diffchange diffchange-inline">There are several pitfalls in </ins>the <ins class="diffchange diffchange-inline">detection of SCRA </ins>in <ins class="diffchange diffchange-inline">samples taken from </ins>the <ins class="diffchange diffchange-inline">patient</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Data availabili</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28387:rev-28396 --> </table>

CaroleHoller04 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28387&oldid=prev 2026-06-01T17:06:29Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:06 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">In summary, </del>JWH-210 <del class="diffchange diffchange-inline">Chemical Powder stands out </del>as <del class="diffchange diffchange-inline">a high</del>-<del class="diffchange diffchange-inline">quality research compound designed for professionals who demand accuracy</del>, <del class="diffchange diffchange-inline">consistency</del>, and <del class="diffchange diffchange-inline">reliability</del>. <del class="diffchange diffchange-inline">This commitment to 5CL ADBA powder quality makes it a trusted option for professionals who require dependable compounds for their work</del>. <del class="diffchange diffchange-inline">From sourcing raw materials </del>to <del class="diffchange diffchange-inline">final packaging</del>, <del class="diffchange diffchange-inline">every stage of the process is monitored to ensure compliance with laboratory</del>-<del class="diffchange diffchange-inline">grade expectations</del>. <del class="diffchange diffchange-inline">This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH</del>-<del class="diffchange diffchange-inline">210 5CL ADBA powder should be considered.&lt;br&gt;How to Choose Powder JWH</del>-<del class="diffchange diffchange-inline">210 &lt;br&gt;This dual</del>-<del class="diffchange diffchange-inline">use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs</del>, <del class="diffchange diffchange-inline">public health researchers</del>, <del class="diffchange diffchange-inline">and customs officials use authentic samples like JWH</del>-<del class="diffchange diffchange-inline">210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes</del>, <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process</del>, <del class="diffchange diffchange-inline">stable composition</del>, and <del class="diffchange diffchange-inline">secure packaging, it remains a valuable resource for laboratory</del>-<del class="diffchange diffchange-inline">based research.&lt;br&gt;Is JWH</del>-<del class="diffchange diffchange-inline">210 Legal? &lt;br&gt;A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration</del>, <del class="diffchange diffchange-inline">respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.</del>) <del class="diffchange diffchange-inline">showed loss of traction, of which 4 showed tremor. Most of the abnormalities </del>were <del class="diffchange diffchange-inline">normalized </del>in <del class="diffchange diffchange-inline">synthetic </del>cannabinoid <del class="diffchange diffchange-inline">treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance</del>&lt;br&gt;&lt;br&gt;Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans &lt;br&gt;This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">High resolution mass spectrometry such as LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS allows the detection and identification of a broad spectrum </del>of <del class="diffchange diffchange-inline">recreational drugs</del>, <del class="diffchange diffchange-inline">including new psychoactive substances. A point</del>-of-<del class="diffchange diffchange-inline">care drugs of abuse (DOA) </del>test <del class="diffchange diffchange-inline">was initially performed on the urine </del>of the <del class="diffchange diffchange-inline">patient. He confirmed drinking 750 ml energy drink without any further consumption </del>of <del class="diffchange diffchange-inline">food and using an e</del>-<del class="diffchange diffchange-inline">cigarette from Gaziantep</del>, <del class="diffchange diffchange-inline">Turkey 10 seconds before </del>the <del class="diffchange diffchange-inline">onset </del>of <del class="diffchange diffchange-inline">his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging </del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availability </del>&lt;br&gt;<del class="diffchange diffchange-inline">The intensity is plotted against the retention time </del>for <del class="diffchange diffchange-inline">both chromatograms, demonstrating the 5CL ADBA powder presence </del>and <del class="diffchange diffchange-inline">elution profiles </del>of <del class="diffchange diffchange-inline">nicotine </del>and <del class="diffchange diffchange-inline">ADB-BUTINACA in </del>the <del class="diffchange diffchange-inline">analysed vape liquid sample</del>. <del class="diffchange diffchange-inline">LC-QTOF</del>-<del class="diffchange diffchange-inline">MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in </del>the <del class="diffchange diffchange-inline">Vape Liquid used by </del>the <del class="diffchange diffchange-inline">patient</del>. <del class="diffchange diffchange-inline">The LC</del>-<del class="diffchange diffchange-inline">QTOF-MS analysis showed </del>that the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">liquid contained nicotine and ADB-BUTINACA </del>(<del class="diffchange diffchange-inline">Fig</del>. <del class="diffchange diffchange-inline">1</del>)<del class="diffchange diffchange-inline">. Because </del>the <del class="diffchange diffchange-inline">point-</del>of-<del class="diffchange diffchange-inline">care DOA test </del>is <del class="diffchange diffchange-inline">generally not able to detect synthetic recreational drug substances</del>, <del class="diffchange diffchange-inline">the liquid </del>of the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette was thereafter screened using liquid chromatography</del>-<del class="diffchange diffchange-inline">quadrupole time</del>-<del class="diffchange diffchange-inline">of</del>-<del class="diffchange diffchange-inline">flight mass spectrometry </del>(<del class="diffchange diffchange-inline">LC-QTOF-MS</del>) on the <del class="diffchange diffchange-inline">Waters™ Xevo G3 QTOF MS system</del>. <del class="diffchange diffchange-inline">After eating a light meal and drinking caffeinated sports drinks </del>at the <del class="diffchange diffchange-inline">ER, </del>the <del class="diffchange diffchange-inline">nausea complaints </del>of the <del class="diffchange diffchange-inline">patient were reduced and the patient was discharged hom</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">All of the compounds tested </del>in the present study <del class="diffchange diffchange-inline">depressed </del>locomotor activity <del class="diffchange diffchange-inline">as is typical for other synthetic cannabinoids </del>(<del class="diffchange diffchange-inline">see review by Wiley </del>et al., <del class="diffchange diffchange-inline">2017</del>). <del class="diffchange diffchange-inline">Average horizontal activity counts</del>/<del class="diffchange diffchange-inline">10 min as a function of time </del>(<del class="diffchange diffchange-inline">10 min bins</del>) and <del class="diffchange diffchange-inline">dose</del>. <del class="diffchange diffchange-inline">Depressant effects of 1</del>.<del class="diffchange diffchange-inline">33 </del>mg/kg <del class="diffchange diffchange-inline">were observed within 10 min following administration </del>and <del class="diffchange diffchange-inline">peak depressant </del>effects <del class="diffchange diffchange-inline">were [https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ 5CL ADBA powder] observed between 0–30 min. Duration </del>of the <del class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0.</del>1 <del class="diffchange diffchange-inline">mg/kg to </del>2.<del class="diffchange diffchange-inline">5 h following 1 mg/k</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">The presence of </del>the <del class="diffchange diffchange-inline">product ion m/z 320</del>, <del class="diffchange diffchange-inline">likely formed from a loss </del>of <del class="diffchange diffchange-inline">carbon dioxide, indicated monohydroxylation at </del>the <del class="diffchange diffchange-inline">tert</del>-<del class="diffchange diffchange-inline">leucine in B8 </del>(<del class="diffchange diffchange-inline">m/z 219</del>)<del class="diffchange diffchange-inline">, butyl side chain in B9 </del>(<del class="diffchange diffchange-inline">m/z 145</del>) <del class="diffchange diffchange-inline">and indazole moiety in B13 (m/z 161</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Demographic </del>and <del class="diffchange diffchange-inline">clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry</del>. <del class="diffchange diffchange-inline">The authors declare that they have no known competing financial interests or personal relationships that could have appeared </del>to <del class="diffchange diffchange-inline">influence </del>the <del class="diffchange diffchange-inline">work reported in this paper</del>. <del class="diffchange diffchange-inline">Second</del>, <del class="diffchange diffchange-inline">we could not 5CL ADBA powder retrieve further detailed information about the e-cigarette that </del>was <del class="diffchange diffchange-inline">used by </del>the <del class="diffchange diffchange-inline">patient such as the label or the region of origin</del>. <del class="diffchange diffchange-inline">Whether a recreational drug can be administered via vaping</del>, <del class="diffchange diffchange-inline">depends on whether </del>the <del class="diffchange diffchange-inline">drug becomes volatile under the evaporation </del>temperature <del class="diffchange diffchange-inline">of the e-cigarette</del>. <del class="diffchange diffchange-inline">Of these samples, 22 contained one or more SCRAs, THC was only detected </del>in <del class="diffchange diffchange-inline">11 samples, only one contained cannabidiol and 6 contained a mixture </del>of <del class="diffchange diffchange-inline">THC and cannabidiol</del>. <del class="diffchange diffchange-inline">There is difficulty </del>in <del class="diffchange diffchange-inline">finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.&lt;br&gt;Data availabili</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">These synthetic cannabinoids act [https://cannabinoidsrc4f-adb.com/ </ins>JWH-210 <ins class="diffchange diffchange-inline">powder] directly at cannabinoid CB1 and CB2 receptors </ins>as <ins class="diffchange diffchange-inline">does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>, <ins class="diffchange diffchange-inline">different metabolism</ins>, and <ins class="diffchange diffchange-inline">often greater toxicity (Fantegrossi et al</ins>.<ins class="diffchange diffchange-inline">, 2014)</ins>. <ins class="diffchange diffchange-inline">Discriminative stimulus effects were tested in rats trained </ins>to <ins class="diffchange diffchange-inline">discriminate Δ9-tetrahydrocannabinol (3 mg/kg</ins>, <ins class="diffchange diffchange-inline">30</ins>-<ins class="diffchange diffchange-inline">min pretreatment)</ins>. <ins class="diffchange diffchange-inline">5F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">PINACA (also known as 5F</ins>-<ins class="diffchange diffchange-inline">ADB</ins>, <ins class="diffchange diffchange-inline">5F-ADB-PINACA)</ins>, <ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">CHIMICA</ins>, <ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA</ins>, <ins class="diffchange diffchange-inline">ADB-FUBINACA</ins>, and <ins class="diffchange diffchange-inline">AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA (also known as FUB</ins>-<ins class="diffchange diffchange-inline">AMB</ins>, <ins class="diffchange diffchange-inline">MMB-FUBINACA</ins>) were <ins class="diffchange diffchange-inline">tested for </ins>in <ins class="diffchange diffchange-inline">vivo </ins>cannabinoid<ins class="diffchange diffchange-inline">-like effects to assess their abuse liabilit</ins>&lt;br&gt;&lt;br&gt;Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans &lt;br&gt;This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporis</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">&lt;br&gt;Subsequently, a one</ins>-<ins class="diffchange diffchange-inline">way analysis of variance was conducted on horizontal activity counts for the 30</ins>-<ins class="diffchange diffchange-inline">min period </ins>of <ins class="diffchange diffchange-inline">maximal effect</ins>, <ins class="diffchange diffchange-inline">and planned comparisons were conducted for each dose against the vehicle control using single degree</ins>-of-<ins class="diffchange diffchange-inline">freedom F </ins>test<ins class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;The chemical structures </ins>of the <ins class="diffchange diffchange-inline">recent synthetic cannabinoids are unlike that </ins>of <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>, <ins class="diffchange diffchange-inline">but are largely based on </ins>the <ins class="diffchange diffchange-inline">structure </ins>of <ins class="diffchange diffchange-inline">older synthetic cannabinoids that are known to have substantial abuse liability (Fig</ins>. <ins class="diffchange diffchange-inline">1&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Locomotor activity in mice was tested to screen </ins>for <ins class="diffchange diffchange-inline">locomotor depressant effects and to identify behaviorally-active dose ranges </ins>and <ins class="diffchange diffchange-inline">times </ins>of <ins class="diffchange diffchange-inline">peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability </ins>and <ins class="diffchange diffchange-inline">act at </ins>the <ins class="diffchange diffchange-inline">CB1 receptor</ins>. <ins class="diffchange diffchange-inline">Tremors were not observed following AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA during </ins>the <ins class="diffchange diffchange-inline">drug discrimination study, but </ins>the <ins class="diffchange diffchange-inline">maximum dose tested was only 0</ins>.<ins class="diffchange diffchange-inline">1 mg/kg, which is 10</ins>-<ins class="diffchange diffchange-inline">fold lower than the dose </ins>that <ins class="diffchange diffchange-inline">produced tremors in </ins>the <ins class="diffchange diffchange-inline">mice. AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA has been implicated in severe adverse effects in recreational users </ins>(<ins class="diffchange diffchange-inline">Adams et al., 2017; Hamilton et al</ins>.<ins class="diffchange diffchange-inline">, 2017</ins>)<ins class="diffchange diffchange-inline">, which suggests that </ins>the <ins class="diffchange diffchange-inline">range between behaviorally active and toxic doses </ins>of <ins class="diffchange diffchange-inline">AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA </ins>is <ins class="diffchange diffchange-inline">narrow. Following that line of reasoning</ins>, <ins class="diffchange diffchange-inline">it should also be noted that some </ins>of the <ins class="diffchange diffchange-inline">more recent compounds produced non</ins>-<ins class="diffchange diffchange-inline">linear dose</ins>-<ins class="diffchange diffchange-inline">effect curves and one compound produced an inverted U</ins>-<ins class="diffchange diffchange-inline">shaped dose</ins>-<ins class="diffchange diffchange-inline">effect, such that intermediate dose fully substituted, but higher doses did not </ins>(<ins class="diffchange diffchange-inline">Gatch and Forster, 2018</ins>)<ins class="diffchange diffchange-inline">. All of the compounds identified as available </ins>on the <ins class="diffchange diffchange-inline">recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al</ins>.<ins class="diffchange diffchange-inline">, 2012&lt;br&gt;&lt;br&gt;Because response suppression may compromise stimulus control, rats failing to complete </ins>at <ins class="diffchange diffchange-inline">least ten responses during </ins>the <ins class="diffchange diffchange-inline">test session were excluded from </ins>the <ins class="diffchange diffchange-inline">analysis </ins>of the <ins class="diffchange diffchange-inline">discriminative stimulus effects of that dose of test compoun</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA </ins>in the present study<ins class="diffchange diffchange-inline">. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the </ins>locomotor activity <ins class="diffchange diffchange-inline">assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg </ins>(<ins class="diffchange diffchange-inline">Gatch </ins>et al., <ins class="diffchange diffchange-inline">2014</ins>)<ins class="diffchange diffchange-inline">, whereas the potency of a recent set was 0.09±0</ins>.<ins class="diffchange diffchange-inline">03 mg</ins>/<ins class="diffchange diffchange-inline">kg </ins>(<ins class="diffchange diffchange-inline">Gatch et al., 2018</ins>)<ins class="diffchange diffchange-inline">, </ins>and <ins class="diffchange diffchange-inline">the potency of the current set is 0</ins>.<ins class="diffchange diffchange-inline">05±0</ins>.<ins class="diffchange diffchange-inline">01 </ins>mg/kg<ins class="diffchange diffchange-inline">. Short-onset, short-acting compounds have a greater abuse liability, </ins>and <ins class="diffchange diffchange-inline">long-acting compounds pose problems of long-acting adverse </ins>effects <ins class="diffchange diffchange-inline">and interactions with other drugs</ins>. <ins class="diffchange diffchange-inline">The duration of action </ins>of the <ins class="diffchange diffchange-inline">synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than </ins>1 <ins class="diffchange diffchange-inline">h, others producing a duration of action between 1–2 h, and others lasting more than </ins>2 <ins class="diffchange diffchange-inline">h</ins>. <ins class="diffchange diffchange-inline">There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Thirty minutes prior to </ins>the <ins class="diffchange diffchange-inline">training sessions</ins>, <ins class="diffchange diffchange-inline">rats received an injection </ins>of <ins class="diffchange diffchange-inline">either vehicle or Δ9-THC and were subsequently placed in </ins>the <ins class="diffchange diffchange-inline">behavior</ins>-<ins class="diffchange diffchange-inline">testing chambers, where food </ins>(<ins class="diffchange diffchange-inline">45-mg food pellets; Bio-Serve, Frenchtown, NJ</ins>) <ins class="diffchange diffchange-inline">was available as a reinforcer for every ten responses </ins>(<ins class="diffchange diffchange-inline">FR10</ins>) <ins class="diffchange diffchange-inline">on a designated injection appropriate leve</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min </ins>and <ins class="diffchange diffchange-inline">0</ins>.<ins class="diffchange diffchange-inline">5 μL of the supernatant was directly injected </ins>to the <ins class="diffchange diffchange-inline">chromatographic system</ins>. <ins class="diffchange diffchange-inline">In the next step</ins>, <ins class="diffchange diffchange-inline">ammonium formate as salting agent </ins>was <ins class="diffchange diffchange-inline">added to </ins>the <ins class="diffchange diffchange-inline">mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min</ins>. <ins class="diffchange diffchange-inline">After vortex-mixing</ins>, the <ins class="diffchange diffchange-inline">mixture was allowed to stand JWH-210 powder at room </ins>temperature <ins class="diffchange diffchange-inline">for 5 min</ins>. <ins class="diffchange diffchange-inline">MS/MS experiments were performed </ins>in <ins class="diffchange diffchange-inline">MRM (multiple reaction monitoring) mode with an isolation window </ins>of <ins class="diffchange diffchange-inline">0.4 m/z</ins>. <ins class="diffchange diffchange-inline">The MS measurement was performed </ins>in <ins class="diffchange diffchange-inline">positive ion mode (except for some acidic compounds such as barbiturates</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28211:rev-28387 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28211&oldid=prev 2026-05-30T18:43:11Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 30. Mai 2026, 18:43 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ 5CLADBA] </del>presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those 5CLADBA </del>of <del class="diffchange diffchange-inline">Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted </del>for <del class="diffchange diffchange-inline">Δ9-THC </del>(<del class="diffchange diffchange-inline">Gamage </del>et al., <del class="diffchange diffchange-inline">2018</del>). <del class="diffchange diffchange-inline">The chemical structures </del>of <del class="diffchange diffchange-inline">the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability </del>(<del class="diffchange diffchange-inline">Fig</del>. 1<del class="diffchange diffchange-inline">)</del>. <del class="diffchange diffchange-inline">All 5 compounds decreased locomotor activity </del>and <del class="diffchange diffchange-inline">produced discriminative stimulus </del>effects <del class="diffchange diffchange-inline">similar to those of Δ9</del>-<del class="diffchange diffchange-inline">THC, which suggests they may have abuse liability similar to that of Δ9-THC</del>. <del class="diffchange diffchange-inline">Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan </del>between <del class="diffchange diffchange-inline">September 2014 and December 2014</del>. <del class="diffchange diffchange-inline">AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.&lt;br&gt;Michael B Gatch &lt;br&gt;</del>Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/<del class="diffchange diffchange-inline">kg. Substantial depressant effects were observed within </del>the <del class="diffchange diffchange-inline">first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 </del>of <del class="diffchange diffchange-inline">8 mice (data not shown). Substantial depressant effects were observed within the first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h </del>at the <del class="diffchange diffchange-inline">highest dose tested </del>(<del class="diffchange diffchange-inline">0.5 mg</del>/<del class="diffchange diffchange-inline">kg</del>)<del class="diffchange diffchange-inline">. Figure 1 shows average horizontal activity counts</del>/<del class="diffchange diffchange-inline">10 min as a function of time (0–4 h</del>) and <del class="diffchange diffchange-inline">dose of Δ9-TH&lt;br&gt;&lt;br&gt;In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes </del>(<del class="diffchange diffchange-inline">HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">LC separates the urine or </del>blood <del class="diffchange diffchange-inline">sample </del>and <del class="diffchange diffchange-inline">QTOF-MS provides </del>high-resolution <del class="diffchange diffchange-inline">and </del>accurate mass <del class="diffchange diffchange-inline">measurements for precise identification and structural elucidation of compounds</del>. The <del class="diffchange diffchange-inline">LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature </del>to <del class="diffchange diffchange-inline">enlarge </del>the <del class="diffchange diffchange-inline">drug aerolisation and bioavailability</del>, <del class="diffchange diffchange-inline">one can elevate the flow rate of air through </del>the e-cigarette <del class="diffchange diffchange-inline">and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users </del>such as <del class="diffchange diffchange-inline">erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt; Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;Inclusion in an NLM database does not imply endorsement of, or agreement with, </del>the <del class="diffchange diffchange-inline">contents by NLM </del>or the <del class="diffchange diffchange-inline">National Institutes </del>of <del class="diffchange diffchange-inline">Health</del>. <del class="diffchange diffchange-inline">It is illegal to sell</del>, <del class="diffchange diffchange-inline">distribute, supply, transport or trade </del>the <del class="diffchange diffchange-inline">pharmaceutical </del>drug under the <del class="diffchange diffchange-inline">Psychoactive Substances Act 2016</del>. <del class="diffchange diffchange-inline">The corresponding indole core analogue</del>, <del class="diffchange diffchange-inline">4F-MDMB-BICA (4F-MDMB-BUTICA)</del>, <del class="diffchange diffchange-inline">has also been widely sold as a designer drug by chemical providers on the internet</del>, <del class="diffchange diffchange-inline">first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products </del>and <del class="diffchange diffchange-inline">sold as </del>a <del class="diffchange diffchange-inline">designer drug since late 2018</del>. <del class="diffchange diffchange-inline">4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) </del>is <del class="diffchange diffchange-inline">an indazole-based synthetic cannabinoid from </del>the <del class="diffchange diffchange-inline">indazole</del>-<del class="diffchange diffchange-inline">3-carboxamide famil</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to 5CL ADBA powder quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 5CL ADBA powder should be considered.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based research.&lt;br&gt;Is JWH-210 Legal? &lt;br&gt;A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance&lt;br&gt;&lt;br&gt;Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans &lt;br&gt;This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl&lt;br&gt;&lt;br&gt;&lt;br&gt;</ins>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the <ins class="diffchange diffchange-inline">5CL ADBA powder </ins>presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">All </ins>of <ins class="diffchange diffchange-inline">the compounds tested in the present study depressed locomotor activity as is typical </ins>for <ins class="diffchange diffchange-inline">other synthetic cannabinoids </ins>(<ins class="diffchange diffchange-inline">see review by Wiley </ins>et al., <ins class="diffchange diffchange-inline">2017</ins>). <ins class="diffchange diffchange-inline">Average horizontal activity counts/10 min as a function </ins>of <ins class="diffchange diffchange-inline">time </ins>(<ins class="diffchange diffchange-inline">10 min bins) and dose</ins>. <ins class="diffchange diffchange-inline">Depressant effects of </ins>1.<ins class="diffchange diffchange-inline">33 mg/kg were observed within 10 min following administration </ins>and <ins class="diffchange diffchange-inline">peak depressant </ins>effects <ins class="diffchange diffchange-inline">were [https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb</ins>.<ins class="diffchange diffchange-inline">com/ 5CL ADBA powder] observed </ins>between <ins class="diffchange diffchange-inline">0–30 min</ins>. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/<ins class="diffchange diffchange-inline">k&lt;br&gt;&lt;br&gt;The presence of </ins>the <ins class="diffchange diffchange-inline">product ion m/z 320</ins>, <ins class="diffchange diffchange-inline">likely formed from a loss </ins>of <ins class="diffchange diffchange-inline">carbon dioxide</ins>, <ins class="diffchange diffchange-inline">indicated monohydroxylation </ins>at the <ins class="diffchange diffchange-inline">tert-leucine in B8 </ins>(<ins class="diffchange diffchange-inline">m</ins>/<ins class="diffchange diffchange-inline">z 219</ins>)<ins class="diffchange diffchange-inline">, butyl side chain in B9 (m</ins>/<ins class="diffchange diffchange-inline">z 145</ins>) and <ins class="diffchange diffchange-inline">indazole moiety in B13 </ins>(<ins class="diffchange diffchange-inline">m/z 161</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Demographic and clinical features are recorded and </ins>blood and<ins class="diffchange diffchange-inline">/or urine samples analysed using </ins>high-resolution accurate mass <ins class="diffchange diffchange-inline">liquid chromatography-mass spectrometry</ins>. The <ins class="diffchange diffchange-inline">authors declare that they have no known competing financial interests or personal relationships that could have appeared </ins>to <ins class="diffchange diffchange-inline">influence </ins>the <ins class="diffchange diffchange-inline">work reported in this paper. Second</ins>, <ins class="diffchange diffchange-inline">we could not 5CL ADBA powder retrieve further detailed information about </ins>the e-cigarette <ins class="diffchange diffchange-inline">that was used by the patient </ins>such as the <ins class="diffchange diffchange-inline">label </ins>or the <ins class="diffchange diffchange-inline">region </ins>of <ins class="diffchange diffchange-inline">origin</ins>. <ins class="diffchange diffchange-inline">Whether a recreational drug can be administered via vaping</ins>, <ins class="diffchange diffchange-inline">depends on whether </ins>the drug <ins class="diffchange diffchange-inline">becomes volatile </ins>under the <ins class="diffchange diffchange-inline">evaporation temperature of the e-cigarette</ins>. <ins class="diffchange diffchange-inline">Of these samples</ins>, <ins class="diffchange diffchange-inline">22 contained one or more SCRAs</ins>, <ins class="diffchange diffchange-inline">THC was only detected in 11 samples</ins>, <ins class="diffchange diffchange-inline">only one contained cannabidiol </ins>and <ins class="diffchange diffchange-inline">6 contained </ins>a <ins class="diffchange diffchange-inline">mixture of THC and cannabidiol</ins>. <ins class="diffchange diffchange-inline">There </ins>is <ins class="diffchange diffchange-inline">difficulty in finding the right information about </ins>the <ins class="diffchange diffchange-inline">NPS, defining their potency and confirmation of their existence in e</ins>-<ins class="diffchange diffchange-inline">liquids or urine samples.&lt;br&gt;Data availabili</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28203:rev-28211 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&diff=28203&oldid=prev 2026-05-30T18:40:37Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 30. Mai 2026, 18:40 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">A limitation </del>of <del class="diffchange diffchange-inline">this case report is that we did not have </del>a <del class="diffchange diffchange-inline">urine sample available for additional NPS testing</del>. <del class="diffchange diffchange-inline">Point</del>-of-care DOA <del class="diffchange diffchange-inline">tests using </del>urine <del class="diffchange diffchange-inline">to screen for misuse </del>of <del class="diffchange diffchange-inline">multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines </del>and <del class="diffchange diffchange-inline">methadone. THC</del>, <del class="diffchange diffchange-inline">methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under </del>the <del class="diffchange diffchange-inline">temperature </del>of <del class="diffchange diffchange-inline">current </del>e-cigarettes, <del class="diffchange diffchange-inline">while crack cocaine is hard to vaporise. A systematic review including data </del>of <del class="diffchange diffchange-inline">114 patients of which the majority was intoxicated due to </del>SCRA <del class="diffchange diffchange-inline">smoking revealed that 45 % of the patients who present at the ER after an </del>intoxication <del class="diffchange diffchange-inline">due to SCRA smoking recovered within 24 hours&lt;br&gt;</del>&lt;br&gt;&lt;br&gt;LC-QTOF-MS <del class="diffchange diffchange-inline">represents a significant advancement </del>in the <del class="diffchange diffchange-inline">field of drug detection, offering higher sensitivity, specificity, </del>and <del class="diffchange diffchange-inline">a broader spectrum of detectable substances</del>. <del class="diffchange diffchange-inline">Despite all negative results in </del>the point-of-care test <del class="diffchange diffchange-inline">for </del>recreational <del class="diffchange diffchange-inline">drugs</del>, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <del class="diffchange diffchange-inline">analysis showed that </del>the <del class="diffchange diffchange-inline">liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid</del>. <del class="diffchange diffchange-inline">We report </del>a <del class="diffchange diffchange-inline">27-year-old man who was admitted to </del>the <del class="diffchange diffchange-inline">emergency room because of sudden [https://cannabinoidsrc4f-adb.com/ read this post from Cannabinoidsrc 4f Adb] this post from Cannabinoidsrc 4f Adb headache</del>, nausea<del class="diffchange diffchange-inline">, vertigo, red eyes </del>and <del class="diffchange diffchange-inline">palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Data availability </del>&lt;br&gt;<del class="diffchange diffchange-inline">When clinical presentation </del>and<del class="diffchange diffchange-inline">/or initial DOA testing results are inconclusive</del>, <del class="diffchange diffchange-inline">additional testing with LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS can be valuable and is recommended</del>. <del class="diffchange diffchange-inline">SCRAs and other NPS may not be detected by point-</del>of-<del class="diffchange diffchange-inline">care DOA tests. In this case</del>, the <del class="diffchange diffchange-inline">point</del>-of-<del class="diffchange diffchange-inline">care DOA urine screening was not able </del>to <del class="diffchange diffchange-inline">detect the synthetic cannabinoid ADB</del>-<del class="diffchange diffchange-inline">BUTINAC</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">As previously mentioned, all </del>of the <del class="diffchange diffchange-inline">compounds tested in </del>the <del class="diffchange diffchange-inline">present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA</del>, and AMB-FUBINACA) <del class="diffchange diffchange-inline">act as agonists </del>at <del class="diffchange diffchange-inline">CB1 receptors </del>(<del class="diffchange diffchange-inline">Banister et al</del>.<del class="diffchange diffchange-inline">, 2015, 2016; Gamage et al</del>.<del class="diffchange diffchange-inline">, 2018</del>)<del class="diffchange diffchange-inline">, which suggests these compounds will produce </del>Δ9-<del class="diffchange diffchange-inline">THC</del>-<del class="diffchange diffchange-inline">like effects</del>, <del class="diffchange diffchange-inline">including abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Morris water maze test was performed to evaluate </del>the <del class="diffchange diffchange-inline">changes in learning and memory function. Only a few case reports about </del>the <del class="diffchange diffchange-inline">dangers </del>of <del class="diffchange diffchange-inline">some synthetic cannabinoids due </del>to <del class="diffchange diffchange-inline">neurotoxicity have been published (Cohen et al.</del>, <del class="diffchange diffchange-inline">2012; McGuinness et al.</del>, <del class="diffchange diffchange-inline">2012; Harris and Brown, 2013; Hermanns et al., 2013). In addition</del>, the <del class="diffchange diffchange-inline">lack of information about neurotoxicity of synthetic cannabinoids could allow abusers consume those substances undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity. The substances used in </del>the <del class="diffchange diffchange-inline">present study both possess naphthoylindole moiety as their parental structure</del>. <del class="diffchange diffchange-inline">(B) </del>The <del class="diffchange diffchange-inline">ratio of damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity to total cells were calculated in nucleus accumben&lt;br&gt;&lt;br&gt;&lt;br&gt;High resolution mass spectrometry such as LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point</del>-<del class="diffchange diffchange-inline">of</del>-<del class="diffchange diffchange-inline">care drugs of abuse (DOA</del>) <del class="diffchange diffchange-inline">test was initially performed </del>on the <del class="diffchange diffchange-inline">urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep</del>, <del class="diffchange diffchange-inline">Turkey 10 seconds before the onset of his </del>first <del class="diffchange diffchange-inline">symptoms</del>. <del class="diffchange diffchange-inline">He usually smokes </del>a <del class="diffchange diffchange-inline">pack of cigarettes a day and sometimes smokes e-cigarettes</del>. <del class="diffchange diffchange-inline">Combined with non</del>-<del class="diffchange diffchange-inline">specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the read this post from Cannabinoidsrc 4f Adb presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB</del>-<del class="diffchange diffchange-inline">BUTINACA </del>(<del class="diffchange diffchange-inline">Bottom) in the Vape Liquid used by the patient. The LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS analysis showed that the e</del>-<del class="diffchange diffchange-inline">liquid contained nicotine and ADB</del>-BUTINACA <del class="diffchange diffchange-inline">(Fig. 1</del>)<del class="diffchange diffchange-inline">. Because the point-of</del>-<del class="diffchange diffchange-inline">care DOA test is generally not able to detect </del>synthetic <del class="diffchange diffchange-inline">recreational drug substances, the liquid of </del>the <del class="diffchange diffchange-inline">e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification </ins>of a <ins class="diffchange diffchange-inline">broad spectrum of recreational drugs, including new psychoactive substances</ins>. <ins class="diffchange diffchange-inline">A point</ins>-of-care <ins class="diffchange diffchange-inline">drugs of abuse (</ins>DOA<ins class="diffchange diffchange-inline">) test was initially performed on the </ins>urine of <ins class="diffchange diffchange-inline">the patient. He confirmed drinking 750 ml energy drink without any further consumption of food </ins>and <ins class="diffchange diffchange-inline">using an e-cigarette from Gaziantep</ins>, <ins class="diffchange diffchange-inline">Turkey 10 seconds before </ins>the <ins class="diffchange diffchange-inline">onset of his first symptoms. He usually smokes a pack </ins>of <ins class="diffchange diffchange-inline">cigarettes a day and sometimes smokes </ins>e-cigarettes<ins class="diffchange diffchange-inline">. Combined with non-specific, transient symptoms</ins>, <ins class="diffchange diffchange-inline">clinical recognition </ins>of SCRA intoxication <ins class="diffchange diffchange-inline">is challenging .</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f-adb.com/ 5CLADBA] presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. </ins>LC-QTOF-MS <ins class="diffchange diffchange-inline">Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) </ins>in the <ins class="diffchange diffchange-inline">Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine </ins>and <ins class="diffchange diffchange-inline">ADB-BUTINACA (Fig. 1)</ins>. <ins class="diffchange diffchange-inline">Because </ins>the point-of-care <ins class="diffchange diffchange-inline">DOA </ins>test <ins class="diffchange diffchange-inline">is generally not able to detect synthetic </ins>recreational <ins class="diffchange diffchange-inline">drug substances</ins>, the <ins class="diffchange diffchange-inline">liquid of the e-cigarette was thereafter screened using </ins>liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <ins class="diffchange diffchange-inline">on </ins>the <ins class="diffchange diffchange-inline">Waters™ Xevo G3 QTOF MS system</ins>. <ins class="diffchange diffchange-inline">After eating </ins>a <ins class="diffchange diffchange-inline">light meal and drinking caffeinated sports drinks at </ins>the <ins class="diffchange diffchange-inline">ER</ins>, <ins class="diffchange diffchange-inline">the </ins>nausea <ins class="diffchange diffchange-inline">complaints of the patient were reduced </ins>and <ins class="diffchange diffchange-inline">the patient was discharged hom&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those 5CLADBA of Δ9-THC (Bannister </ins>and <ins class="diffchange diffchange-inline">Connor, 2018)</ins>, <ins class="diffchange diffchange-inline">and MDMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA fully substituted for Δ9</ins>-<ins class="diffchange diffchange-inline">THC (Gamage et al., 2018)</ins>. <ins class="diffchange diffchange-inline">The chemical structures of the recent synthetic cannabinoids are unlike that </ins>of <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>, <ins class="diffchange diffchange-inline">but are largely based on </ins>the <ins class="diffchange diffchange-inline">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9</ins>-<ins class="diffchange diffchange-inline">THC, which suggests they may have abuse liability similar to that </ins>of <ins class="diffchange diffchange-inline">Δ9-THC. Subsequent testing identified 5F</ins>-<ins class="diffchange diffchange-inline">ADB </ins>to <ins class="diffchange diffchange-inline">have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA produced tremors and may be of increased risk in human recreational users.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gatch </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Duration </ins>of the <ins class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min</ins>, and <ins class="diffchange diffchange-inline">maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg </ins>AMB-FUBINACA <ins class="diffchange diffchange-inline">in 3 of 8 mice (data not shown</ins>)<ins class="diffchange diffchange-inline">. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h </ins>at <ins class="diffchange diffchange-inline">the highest dose tested </ins>(<ins class="diffchange diffchange-inline">0</ins>.<ins class="diffchange diffchange-inline">5 mg/kg)</ins>. <ins class="diffchange diffchange-inline">Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h</ins>) <ins class="diffchange diffchange-inline">and dose of </ins>Δ9-<ins class="diffchange diffchange-inline">TH&lt;br&gt;&lt;br&gt;In</ins>-<ins class="diffchange diffchange-inline">vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15</ins>,<ins class="diffchange diffchange-inline">16</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt; Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Inclusion in an NLM database does not imply endorsement of, or agreement with, </ins>the <ins class="diffchange diffchange-inline">contents by NLM or </ins>the <ins class="diffchange diffchange-inline">National Institutes </ins>of <ins class="diffchange diffchange-inline">Health. It is illegal </ins>to <ins class="diffchange diffchange-inline">sell</ins>, <ins class="diffchange diffchange-inline">distribute</ins>, <ins class="diffchange diffchange-inline">supply</ins>, <ins class="diffchange diffchange-inline">transport or trade </ins>the <ins class="diffchange diffchange-inline">pharmaceutical drug under </ins>the <ins class="diffchange diffchange-inline">Psychoactive Substances Act 2016</ins>. The <ins class="diffchange diffchange-inline">corresponding indole core analogue, 4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BICA (4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BUTICA</ins>)<ins class="diffchange diffchange-inline">, has also been widely sold as a designer drug by chemical providers </ins>on the <ins class="diffchange diffchange-inline">internet</ins>, first <ins class="diffchange diffchange-inline">being identified in May 2020</ins>. <ins class="diffchange diffchange-inline">It has been used as an active ingredient in synthetic cannabis products and sold as </ins>a <ins class="diffchange diffchange-inline">designer drug since late 2018</ins>. <ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA </ins>(<ins class="diffchange diffchange-inline">also known as MDMB</ins>-<ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">BINACA using systematic EMCDDA nomenclature or 4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-BUTINACA) <ins class="diffchange diffchange-inline">is an indazole</ins>-<ins class="diffchange diffchange-inline">based </ins>synthetic <ins class="diffchange diffchange-inline">cannabinoid from </ins>the <ins class="diffchange diffchange-inline">indazole</ins>-<ins class="diffchange diffchange-inline">3</ins>-<ins class="diffchange diffchange-inline">carboxamide famil</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28195:rev-28203 --> </table>

ScarlettCagle66